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ABSTRACT 
Multiple sclerosis (MS) and rheumatoid arthritis (RA) are chronic inflammatory diseases 
where genetic and environmental factors influence the pathogenesis. MS is a disease of the 
central nervous system, while RA primarily affects the joints. Biopharmaceuticals such as 
interferon beta (IFNβ) and tumor necrosis factor-alpha (TNF-α) inhibitors are widely used 
treatments to achieve a reduction in disease activity in people with MS and RA respectively. 
Over time, however, some of the treated patients develop anti-drug antibodies (ADA) or 
neutralizing ADA (NAb) that can reduce or abrogate the drug efficacy and subsequently lead 
to loss of clinical response. 
Five studies are included in this thesis, which assess endogenous immune processes affected 
and evaluates laboratory methods used for monitoring immunogenicity of IFNβ and TNF-α 
inhibitors. Collectively, the findings presented in this thesis aim to optimize methods for drug 
level and ADA screening to allow for easier treatment decisions. Additionally, the thesis 
highlights the skin site as a potential contributor to ADA development.  
In study I, we studied the immunomodulatory role of IFNβ and how it was affected by NAb. 
We found a 3-fold increase of serum IL-7 (genetically associated with MS) in IFNβ treated MS 
patients and this was related to the lowered IL-7Rα expression on cell surfaces. The presence 
of high NAb titers to IFNβ resulted in significantly lower serum IL-7 levels compared to NAb 
negative patients as measured with the myxovirus resistance protein A (MxA) gene 
expression assay (MGA). Since the MGA method is cumbersome we decided to evaluate a 
new method, iLite (in study II). We found that the NAb titers had a high degree of correlation 
between the two assays and that NAb titers of 150 TRU/mL were suggestive of significant 
neutralization of the drug. However, in the iLite assay (and MGA) NAb titers are calculated 
using the Kawade principle and this method has statistical limitations. In study III, we 
therefore continued to validate the iLite assay using a cut-point approach designed to be 
more sensitive and statistically accurate. By using the cut-point approach, we identified 12% 
more NAb positive samples compared to using the Kawade method, showing the increased 
sensitivity achieved with the cut-point design. In study IV, we evaluated different methods 
for ADA screening of the TNF-α inhibitor infliximab. We showed that ADA could be detected 
in the majority of samples with low drug levels using ELISA, but that samples with detectable 
drug levels also tested ADA positive using an acid and dissociation assay (PandA). Thus, the 
PandA proved useful as a complement to the routinely available ELISA to monitor 
immunogenicity. Lastly (in study V), to understand the mechanism of ADA induction, we 
investigated the primary immune response against repetitive injections with biologicals in 
skin cells. Using a human skin model, we found that the IFNβ injection enhanced dendritic cell 
maturation and elevated the expression of several inflammatory cytokines, which suggest 
that the administration triggers an immune response at the injection site.  
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1 BACKGROUND 
1.1 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) 
and can cause significant disability (1, 2) and premature death (1). Symptoms can vary greatly 
since any part of the CNS can be affected. Symptoms can include impairment of balance, 
mobility, vision and cognitive function (3) (Fig. 1). Among adults under 40 years of age, MS is 
one of the most common neurological disorders and affects ≈ 2.3 million people worldwide 
(4). The average age of disease onset is approximately 30 years and woman are more than 
twice as likely as men to develop MS (the female to male ratio 2.35:1) (5) (Fig. 2).  
 
 
 
 
 
 
 
 
 
1.1.1 Prevalence and incidence   
The prevalence of MS varies greatly depending on the latitude (6). North America and Europe 
have the highest prevalence (140 and 108 per 100,000 respectively) while Sub-Saharan Africa 
and East Asia have the lowest prevalence (2.1 and 2.2 per 100,000). Sweden has the highest 
prevalence of MS in Europe (188.9 per 100,000) (5), and Albania has the lowest (22 per 
100,000) (MS International Federation, MS Atlas 2013), showing that the north-south 
gradient is present even within Europe. In Sweden, the average MS incidence from 2001 to 
2008 were 10.2 per 100.000 (7). The incidence is thus considerably higher than previous 
estimates of 4.3 (8) and 6.4 (9) making Sweden among the highest nationwide incidence 
estimates reported (7). 
1.1.2 Diagnosis  
Magnetic resonance imaging (MRI) of the brain together with the patient’s disease symptoms, 
both specific for MS, are important for the diagnosis. Expanded Disability Status Scale (EDSS) 
Fig. 1. Frequency of MS symptoms. 
Adapted with permission MS International 
Federation, MS Atlas 2013. 
Fig. 2. Gender ratio in MS.  
Adapted with permission from MS 
International Federation, MS Atlas 2013. 
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(10), together with MRI (11) are used as quantitative measures of disability and disease 
activity. According to the McDonald criteria (2001), diagnosis of MS is based on the finding of 
dissemination of lesions in space (DIS) and time (DIT) i.e. two separate MS specific CNS lesions 
on brain MRI that have occurred in two or more separate events (12, 13). The first event is 
referred to as a clinically isolated syndrome (CIS), and the second event confirms the diagnosis 
of MS provided that differential diagnoses are excluded. Immunoglobulin (Ig) production is a 
common feature in people with MS and is characterized by synthesis of IgG, IgM and IgA (14-
16) and the presence of two or more oligoclonal bands in the cerebrospinal fluid. These bands 
are of diagnostic value since it can be found in up to 95% of people with MS (17). In 2017 the 
McDonald criteria was revised to allow earlier diagnosis of MS and treatment initiation. The 
new criteria suggests that an MS diagnosis of CIS patients can be done based on DIS and the 
presence of oligoclonal bands in the cerebrospinal fluid, which the latter can replace evidence 
of DIT (18). 
1.1.2.1 Disease courses 
Four MS disease courses were defined in 1996, including relapsing remitting (RR), primary 
progressive (PP), progressive relapsing (PR) and secondary progressive (19) (Fig. 3). However, 
the disease phenotypes of MS are constantly being re-examined and new recommendations 
were provided in 2013 (20). The main changes were the addition of CIS and removal of PRMS. 
Around 85% to 90% of people with MS present with an RR disease course (RRMS) (21, 22). 
RRMS is characterized by disease episodes known as relapses that are followed by periods of 
remission where complete or partial clinical recovery of symptoms is gained (22). Relapses 
are caused by inflammation and demyelination in the CNS (23, 24). One to two decades 
following an MS diagnosis most of the people with RRMS (80%) proceed to develop a 
secondary progressive phase (SPMS). The disease course worsens without periods of recovery 
due to increased axonal loss and decrease in brain volume. Approximately 10% to 15% of the 
people with MS present with a primary progressive disease course from the onset of the 
disease (PPMS) (1, 23, 25), and a decreased diagnosis of PPMS have been observed in Sweden 
after introduction of disease-modifying therapies (DMT) (26). Progressive relapsing MS 
(PRMS) is the least prevalent form and only affects around 5% of the people diagnosed with 
MS. 
Fig. 3. Classification of MS. Adapted with permission from MS International 
Federation, MS Atlas 2013. 
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1.1.3 The immunopathology  
The cause of MS is, to date, unknown but evidence suggests that the natural tolerance of the 
immune system breaks when antigen presenting cells present self-antigen, such as parts of 
myelin together with co-stimulatory signals, and thereby can begin to mount an immune 
response to these self-antigens (27).  
Loss of self-tolerance has been suggested to occur through molecular mimicry (28), for 
example, if foreign pathogens share structural similarities with self‐antigens. Once the 
peripheral immune cells are activated they can infiltrate the CNS through the compromised 
blood brain barrier. Infiltration allows acute inflammation, myelin destruction, axonal injury 
(29) and neurodegeneration (30). The infiltrating cells, mostly macrophages and T cells, form 
perivascular inflammatory lesions (plaques) and promote disruption of neurological axonal 
signaling (24). When infiltrating cells interact with activated CNS-resident cells including local 
tissue resident antigen presenting cells such as microglia it leads to destruction of 
oligodendrocyte-produced myelin. Cross-reactivity between an endogenous protein and a 
pathogenic protein might also initiate activation of T cells (31).  
MS was previously considered to be a T cell-mediated disease since autoreactive myelin-
specific cluster of differentiation (CD)4+ T cells (32, 33) and CD8+ T cells (34, 35) were found in 
MS lesions. More recently interleukin (IL)-17 producing T cells have also been suggested as 
key players in the pathogenesis of MS (36-38). Furthermore, MS is characterized by the 
elevated production of T helper (Th) 1 proinflammatory cytokines TNF-alpha (TNF-α), IL-2, 
and IFN-gamma (IFNγ) (39, 40), whereas anti-inflammatory Th2 cytokines IL-4 and IL-10 are 
downregulated (41). However, B cells have also now been recognized as important in the 
pathogenesis of MS (42, 43). Two randomized placebo-controlled phase 2 trials have shown 
that the disease activity in RRMS and PPMS were reduced after B cell depletion using anti-
CD20 monoclonal antibody (mAb) (rituximab) (44, 45). Another anti-CD20 mAb (ocrelizumab) 
was associated with lower rates of disease activity and disability worsening than IFNβ-1a 
treatment of RRMS and PPMS in three phase 3 trials (46). These drugs are thought to exert 
their effect on B cells by reducing their capacity to present antigens and ability to secrete 
cytokines (42).  
1.1.4 Risk factors 
The etiology of MS is considered multifactorial where both genetics and environment 
influence pathogenesis (47).  
1.1.4.1 Genetic factors 
In terms of genetic association MS is not considered to be inherited. However, there is 
evidence that genetic variations affect the risk of MS (48) and whole genome association 
studies have traced more than 200 genetic regions outside the human leukocyte antigen 
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(HLA) to be associated to MS (49). A haplotype within the HLA region (DRB1*15:01) is 
associated with a three-fold increased risk of the disease (50), whereas HLA-A*02 has shown 
to have a protective effect (51, 52).  
The IL-2 receptor (IL2R) and IL-7 receptor (IL7R) genes are also well established genetic factors 
contributing to MS risk (53). The IL-7R is one of the most studied gene polymorphisms and 
may play a role in MS (54, 55). The IL-7R is a heterodimer that consists of the IL-7Rα chain 
(CD127), which is shared with thymic stromal lymphopoietin and the common cytokine γ 
chain (CD132) (Fig. 4) (56). 
 
1.1.4.2 Environmental factors 
Epstein-Barr virus (EBV) infection causing infectious mononucleosis, and cigarette smoking, 
are the best confirmed environmental contributors associated with MS (57). Moreover, 
vitamin D deficiency (6, 58) has also been suggested to contribute to disease pathogenesis.  
1.1.4.2.1 Virus  
A higher frequency of EBV seropositivity has been reported in MS patients compared to 
controls (59). A majority of people who become infected with EBV are asymptomatic but the 
virus can in some individuals cause a lymphoid infection, clinically known as infectious 
mononucleosis (60), which has been associated with a 2-fold risk of developing MS (61). 
Infection with human herpesvirus 6 (HHV-6) has also been indicated to play a role in MS 
pathology. One of the first studies that showed an association between HHV-6 and MS was 
presented by Challoner and colleagues that showed that HHV-6 was expressed in plaques of 
individuals with MS (62).  
1.1.4.2.2 Cigarette smoking  
Cigarette smoking contributes to the risk of developing MS, with an odds ratio of 1.5 for 
smokers versus non-smokers (63) and contributes to accelerated disease progression (64-66). 
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Smokers that are carriers of the HLA-DRB1*15 allele have a further increased risk of 
developing MS (67). In contrast, oral tobacco users are thought to have a decreased risk to 
develop MS (68). Therefore it is suggested that risk of MS may be associated with lung 
irritation (69), which is supported by that smoking causes inflammation in the lung (70). 
1.1.4.2.3 Vitamin D  
The link between autoimmune diseases and poor vitamin D levels is still unclear but low 
vitamin D levels and limited sun exposure have been linked to an increased risk of developing 
MS (6, 58). This notion was further supported in a recent paper which evaluated the 
association between vitamin D and the risk of MS using a nested case-control design (71). 
Using the Finnish maternity cohort, they analyzed serum samples from 1,092 women 
diagnosed with MS and 2,123 women without MS. They found that 1 in 2 women (with and 
without MS) had vitamin D deficiency, and 1 in 3 had vitamin D insufficiency. On average, 
vitamin D levels were lower in MS patients than controls. Interestingly the authors found that 
with each 50 nanomol/liter increase in vitamin D the risk of MS was lowered by 39% (71). 
Despite several studies showing an association between low vitamin D levels and a higher risk 
of MS, the impact of vitamin D supplementation on MS activity still warrant further 
investigation (72). 
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1.2 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a heterogonous autoimmune disease characterized by synovial 
inflammation that can lead to joint destruction, but also systemic inflammation that can result 
in impaired movement and disability. Inflammatory symptoms include joint stiffness, 
swelling, pain and primarily affects the joints in the hands and feet (73). Before menopause 
women are three times more likely to develop the disease than men indicating that hormones 
play an important role in the pathogenesis (Fig. 5). RA is the most common inflammatory joint 
disease affecting 0.5% to 1% of the adult population globally (74). As RA progresses, continued 
inflammation results in permanent damage to cartilage, bone, tendons, ligaments and 
consequently results in joint destruction and disability. 
 
 
 
 
1.2.1 Diagnosis 
Diagnosis of RA is based on different classification criteria, the older developed by the 
American College of Rheumatology (ACR) in 1987 (75), and the more recent by the ACR and 
European League Against Rheumatism (EULAR) that was designed to capture patients earlier 
at onset of disease (76). To be classified as RA using the older criteria set (ARC), patients were 
required to fulfill at least four out of seven criteria including morning stiffness, arthritis of ≥3 
joints, arthritis of the hand joints, symmetric arthritis, rheumatoid nodules, rheumatoid factor 
(RF), and radiographic changes (75). However, some of the criteria are rarely fulfilled in the 
first year after RA onset (77, 78). Since an early diagnosis of RA, and subsequent early 
therapeutic intervention, is crucial to halt the disease progression and joint destruction there 
was a need to find a diagnostic method for early stage diagnosis (79). Thus, in 2010, the 
EULAR/ACR criteria was launched which captured about 50% of patients earlier, and included 
not only RF (as in the older criteria), but also the more specific anti-citrullinated protein 
antibodies (ACPA) (80, 81). The presence of RF or ACPA (usually measured with the anti-cyclic 
citrullinated peptide (CCP) test), is associated with greater joint damage (82). ACPA can be 
present up to 10 years prior to RA diagnosis and is thus a valuable biomarker. Today 
individuals with joint pain and positive anti-CCP are often monitored and sometimes treated 
early, despite not meeting the ARC diagnostic criteria (83). 
1.2.2 The immunopathology  
Production of autoantibodies, including RF and ACPA, that target self-proteins constitute a 
significant part of RA disease pathogenesis. RF of the IgM isotype are most common, but the 
Fig. 5. Gender ratio in RA.  
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IgA and IgG class of RF can also be detected (84), where IgA has been associated to a more 
destructive disease course (85). The prevalence of RF in healthy individuals is less than 5%, 
whereas RA patients have a frequency of 70% to 90% (86). RF are generally of low affinity and 
directed to the fragment crystallizable (Fc) region of IgG (82). Disease symptoms can progress 
by the formation of immune complexes between the RF and IgG (Fig. 6) (87), which may in 
turn, activate the complement system resulting in increased inflammation. 
 
 
ACPA are strongly associated with RA. ACPA-producing B cells and plasma cells can be found 
in both the synovium and circulation and are of IgG, IgA, or IgM isotype (88). These antibodies 
are directed against peptides and proteins that are citrullinated (conversion of arginine on 
the B cell epitope into citrulline) and are found not only in the joints of patients with RA but 
also in the gum and lungs. Smoking, a strong risk factor for RA as described below, is known 
to induce citrullination. ACPA are pathogenic as they can trigger immune cell activation and 
several studies have showed that immune complexes (containing ACPA) triggered TNF-α 
secretion by macrophages (83). 
In addition to the characteristic autoantibodies (RF and ACPA) observed in two-thirds of the 
patients, the pathophysiology of RA is characterized by an overproduction of 
proinflammatory cytokines, where TNF-α is thought to be the most dominant (89). TNF-α 
induce an increased production of other proinflammatory cytokines including IL-1, IL-6, and 
IL-8. These cytokines promote T cell activation and induce expression of adhesion molecules 
on endothelial cells, and the process leads to increased T cell infiltration. Additionally, 
proinflammatory cytokines increase the expression of vascular growth factors that stimulate 
angiogenesis and proliferation of keratinocyte that support osteoclast differentiation and 
maturation - the primary cell responsible for bone destruction (90). 
Since there is a higher prevalence of women that develop RA it has been suggested that 
hormones could play a role in the disease. The disease often manifests during childbearing 
Fig. 6. Immune complex formation between IgG and RF.  
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years, with a peak post-partum, and the disease symptoms often improve during pregnancy 
(91). Breast-feeding, oral contraceptives or hormone replacement therapy post-menopausal 
are associated with decreased risk of developing RA (92, 93). Moreover, men with RA have 
been found to have decreased levels of sex hormones especially testosterone (94). 
1.2.3 Risk factors  
1.2.3.1 Genetics 
The heritability of RA is estimated to be around 40% and is higher for sero-positive (RF+) than 
seronegative (RF-) RA (95), and the concordance rate in monozygotic twins is up to 15% (96). 
More than 100 genetic loci have been associated with RA (97), where HLA and protein 
tyrosine phosphatase non-receptor 22 have the strongest associations (98, 99).  
The main genetic risk factor for RA has been known for over 30 years and is the so called 
‘shared epitope’. The term refers to that the majority of RA patients share a five amino acid 
sequence coded by several HLA-DRB1 alleles (100). The ‘shared epitope’ is associated with 
the ACPA positive RA subset (101). 
1.2.3.2 Environmental factors 
1.2.3.2.1 Cigarette smoke 
Several epidemiological studies have identified smoking to be one of the strongest 
environmental risk factors for developing RA (102-104). A meta-analysis conducted by 
Sugiyama and colleagues showed that the risk of developing RA was about twice as high for 
smokers than for non-smokers, and that female smokers had a 1.3-times higher risk than for 
non-smokers (102). Furthermore, they showed that smoking is an even greater risk factor for 
RA in RF-positive men and for heavy smokers (102).  
1.2.3.2.2 Microbiota 
Some studies have indicated that changes in the function of gut microbiota are associated 
with RA (105). Chen and colleagues found that RA patients had a decreased diversity of gut 
microbiota compared with healthy individuals (106), and Vaahtovuo et al. found a reduced 
composition of microbiota in patients with early onset of RA (107). However, the largest 
epidemiological study to date found that common infections in the gastrointestinal or 
urogenital tract were associated with a strongly reduced risk of RA (108), thus it is yet unclear 
whether, and how, infections may eventually trigger or have a protective role in RA.   
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1.3 BIOPHARMACEUTICALS 
Biopharmaceuticals, although expensive, have proved economically viable for treatment of 
incurable chronic diseases such as MS and RA by reducing the rate of disease progression and 
therefore the long-term health burden of these diseases. For MS and RA there are now several 
therapies targeting the immune system, the major agents being IFNβ and TNF-α-inhibitors, 
respectively. 
1.3.1 Therapies for multiple sclerosis  
DMT have been shown to significantly reduce the relapse rate and demyelination in MS, as 
measured by MRI scans. DMT are capable of modulating the immune system and have 
immunosuppressive properties. Currently there are eight injectable, three oral and three 
infused DMT available to treat MS. Those that are approved by the U.S. Food and Drug 
Administration (FDA) for treatment of relapsing MS include IFNβ which is often used as a first-
line treatment.  
1.3.1.1 Interferon beta 
IFNβ is a naturally occurring pleiotropic cytokine that is secreted by fibroblasts, epithelial cells, 
NK cells, and leukocytes as a response mechanism to viral infections (109). The biological 
activity of IFNβ is initiated when IFN binds to the Type I IFN receptors (subunits IFNAR1 and 
IFNAR2) (110) that are located on the surface of most cell types (111). The binding activates 
the Janus Activated Kinase 1 (JAK1) and Tyrosine Kinase 2 (TYK2), that in turn phosphorylate 
transcription factors Signal Transducer and Activator of Transcription (STAT) 1 and STAT2 
(112, 113). Phosphorylation leads to dimerization and association with Interferon 
Regulatory Factor 9 (IRF9) to form the IFN-Stimulated Gene Factor 3 (ISGF3). ISGF3 binds to 
IFN-Stimulated Response Elements (ISRE) in the cell nucleus (Fig. 7) (114). Even though the 
binding induces expression and transcription of genes, which function is to target viral 
infections (115), it is difficult to pinpoint the precise mechanism of IFNβ treatment.  
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1.3.1.1.1 IFNβ product properties 
Two types of recombinant IFNβ preparations are available for treatment of MS; IFNβ-1a 
(Avonex®/Rebif®/Plegridy®), and IFNβ-1b (Betaferon®/Extavia®). Differences in terminology 
between the two recombinant proteins are based on the sequence difference (116). The 
recombinant versions of IFNβ show a high structural homology with the endogenous IFNβ. 
IFNβ-1a is produced in Chinese hamster ovary cells (117) and has the same amino acid 
sequence and glycosylation structure as the endogenous protein (118). The glycosylation 
reduces protein aggregation and increases protein stability and solubility (119). IFNβ-1a is 
administrated either intramuscularly (i.m.) of 6 million units (30 µg) once a week (Avonex®), 
or subcutaneously (s.c.) with 12 million units (44 µg) three times weekly (Rebif®). The most 
recently approved IFNβ-1a formulation is PEGylated (Plegridy®) and is administrated s.c. of 
12 million units (125 µg) every fortnight. IFNβ-1b is produced in Escherichia coli (120) and 
differs from endogenous IFNβ protein as it is not glycosylated, lacks one amino acid, and has 
a replacement of the cysteine to a serine at position 17 (121-123). The amino acid changes 
are important for the stability of the molecule since it prevents the formation of incorrect 
disulfide bonds. IFNβ-1b (Betaferon®/Extavia®) is administrated of 8 million units (250 µg) s.c. 
every other day. Despite the fact that there is a 70% resemblance between the recombinant 
IFNβ preparations it has been suggested that IFNβ-1a has a 10-fold increased capacity over 
IFNβ-1b to induce antiviral, anti-proliferative and immunomodulatory activity. The difference 
between the molecules is thought to be caused by glycosylation-induced stabilization in IFNβ-
1a (124). The s.c. injection is administered as a bolus into the subcutis and the i.m. injection 
delivers the medication deep into the muscle, allowing the medication to be absorbed into 
the bloodstream quickly (Fig. 8). 
 
1.3.1.1.2 Mechanism of action 
In clinical trials, the use of IFNβ has been shown to decrease the relapse rate by about one-
third (125, 126), reduce the development of new brain lesions (127-130), and slow 
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progression (131-134) as measured with the EDSS score (135-137). However, the clinical 
response rate to IFNβ is highly heterogeneous and some patients experience continued 
disease activity (138). It is suggested that MRI can be used to monitor the treatment effect of 
IFNβ where the development of MRI lesions within 6 to 24 months after treatment initiation 
defines a poor responder patient (138). IFNγ and IFNα have also been investigated as 
potential therapeutics in MS. However, IFNγ was found to worsen the disease symptoms, and 
IFNα did not exhibit as improved effect on the relapse rate as compared to IFNβ (139). The 
molecular mechanisms of IFNβ are complex and alter the expression of several hundreds of 
genes (140), including the IFNβ biomarker Myxovirus resistance protein A (MxA) used to 
identify treatment responders (141). Therapeutic effects of IFNβ includes i) increased anti-
inflammatory cytokine production and reduced proinflammatory cytokine production, ii) 
reduced cell migration across the blood-brain barrier, iii) promoted CNS repair, and iv) anti-
proliferative properties. 
i. Treatment with IFNβ reduces Th1 proinflammatory cytokines IL-17 (142), TNF-α and 
IFNγ (143), and shifts the cytokine profile towards a Th2 profile and increased levels 
of anti-inflammatory cytokines such as IL-4 and IL-10 (144). For example, Liu and 
colleagues studied peripheral blood mononuclear cells (PBMCs) from MS patients 
before and after IFNβ-1a treatment and found significant changes in IL-10 expression 
two days after treatment initiation (145).  
 
ii. Several in vitro studies have shown that T cells have a decreased capacity to interact 
with endothelial cells since IFNβ alters the expression of several adhesion molecules 
(146). For example, treatment with IFNβ lowered the serum levels of the matrix 
metalloproteinase (MMP)-9 and increased expression of tissue inhibitor 
metalloproteinase (TIMP)-1 (147, 148), which resulted in reduced numbers of MRI 
lesions (148). Furthermore, T cells subjected to IFNβ downregulate cell surface 
expression of the alpha 4 integrin (149) and increase expression of soluble vascular 
cell adhesion protein (VCAM) 1 in MS patients serum. Increases in soluble VCAM1 
correlated with decreased MRI lesions suggesting that IFNβ interfere with the 
adhesion cascade and thus might prevent T cells from entering the CNS (150).  
 
iii. IFNβ has been suggested to promote CNS repair by increased nerve growth factor 
mRNA after IFNβ treatment of astrocyte in vitro (151) and a study by Biernacki et al. 
saw that IFNβ could repair damage in the CNS by promoting the production of nerve 
growth factor in MS patients (152). The authors suggest that increased nerve growth 
might explain why early treatment with IFNβ can reduce the rate of brain atrophy 
(152).  
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iv. Studies have shown that leukocyte and lymphocyte counts were reduced as a result 
of IFNβ treatment (153) and a reduction of white blood cells has also been observed 
(154). Moreover, McKay et al. showed that treatment with IFNβ reduced the antigen 
presenting cells ability to present antigen, which led to reduced T cell responses (155). 
1.3.1.1.3 Prediction of treatment efficacy  
Identification of biomarkers that could be used to find patients who are likely to respond to 
IFNβ treatment is highly warranted (138). In 2010, Axtell and colleagues found that the 
efficacy of IFNβ could be predicted in RRMS where non-responders to IFNβ had higher serum 
IL-17F concentration before treatment initiation compared to responders (156). Moreover, a 
paper by Lee et al. that suggested that high serum IL-7 levels, when paired with low IL-17F 
serum levels, predicted a good response to IFNβ (157). However, when the same group 
replicated this finding in a validation cohort it could not be confirmed (158).  
Several studies have investigated gene expression for use as biomarkers to evaluate the 
response to IFNβ (138). Two studies have shown that IL-8 gene expression was 
downregulated in MS patients who had a good response to IFNβ treatment (159, 160), and a 
genome-wide association study identified 47 genes that could distinguish IFNβ responders 
from non-responders (161). 
1.3.1.1.4 Side effects related to IFNβ treatment 
A recent case-control study showed that RRMS patients on IFNβ treatment had a 1.8- and 1.6-
fold increased risk of migraine or stroke, and a 1.3-fold increased risk of developing 
depression and hematologic abnormalities, compared to MS patients on non-IFNβ disease-
modifying drugs (162). Furthermore, a meta-analysis including nine clinical trials showed that 
IFNβ treated patients had a 2.8-fold increased risk of discontinuing treatment due to adverse 
events like flu-like symptoms, leukopenia, lymphopenia and elevated liver enzymes and 
injection site reactions (163).  
Local cutaneous injection site reactions can cause symptoms such as eczema, swelling, pain 
and redness/erythema of the skin at the injection site (164). These symptoms can appear 
either immediately following IFNβ administration or several years after treatment initiation 
(165). As many as 96% of MS patients that are given s.c. administration with IFNβ get a skin 
reaction compared to i.m. IFNβ administration that only has a 33% reported incidence of skin 
reactions (166). Why such local skin reactions occur is not clear but may be due both to the 
administration and the biopharmaceutical composition. If the patient uses the wrong 
injection technique and the IFNβ is injected into the epidermis instead of the s.c. tissue it 
could potentially cause cutaneous adverse events. Also, the IFNβ formulation itself is 
observed to be inflammatory trough chemokine induction followed by immune cell 
extravasation. A study by Buttmann and colleagues showed that skin biopsies sampled 24 
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hours after IFNβ injection had strong Contaminant Candidate List 2 and CXC chemokine ligand 
(CXCL) 10 expression that initiated T cell trafficking from the circulation and infiltration into 
the skin tissue (167). It has also been reported that cutaneous psoriasis can be the caused by 
administration of IFNβ (164, 168). A study recently published showed that almost all 
regulatory T cells in normal human skin have a memory phenotype. Under steady-state 
conditions, the skin resident memory regulatory T cells are relatively unresponsive. However, 
in inflamed skin from psoriasis patients, memory regulatory T cells are highly proliferative and 
produce low levels of IL-17 (169). Immunohistochemistry of a skin biopsy from one MS patient 
that developed psoriasis after IFNβ injection revealed IL-17 expressing cells, suggesting that 
these cells might be defective (164).  
1.3.1.2 Natalizumab 
Natalizumab (Tysabri®) is a humanized monoclonal IgG4 antibody produced in murine 
myeloma cells. Treatment with natalizumab is a highly effective for RRMS and has shown in 
two randomized controlled trials to significantly reduce relapse rate by 68% and disease 
progression (170, 171). The drug is administrated intravenously with a dose of 300 mg every 
4 weeks as recommended by the FDA and the European Medicine Agency. Natalizumab 
targets the very late antigen 4, composed of alpha 4 and beta 1 that is expressed on the 
surface of leukocytes and thereby prevents interaction with its ligand VCAM1 present on 
blood vessels (Fig. 9). Therefore, activated immune cells will be blocked to migrate into the 
inflamed brain (172, 173) as illustrated below.  
Fig. 9. Natalizumab inhibits leukocytes migration across the blood 
brain barrier (BBB) into the CNS. 
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1.3.2 Mechanism of action 
A study by Kivisakk and colleagues showed that treatment with natalizumab increased the 
proportion proinflammatory cytokines including TNF-α, IFNγ, IL-17, and IL-2 in peripheral 
blood (174). Altered cytokine expression could be a consequence of preventing activated T 
cells to migrate from the peripheral circulation (174). MS patients treated with natalizumab 
have significant increased B cell counts in peripheral blood (175) suggesting interference with 
B cell homing. It´s been proposed that the interference could lead to impaired differentiation 
of plasma cells. This theory is support by Selter et al. who showed that IgM and IgG levels in 
serum were significantly decreased in natalizumab treated patients compared to treatment 
naïve patients (176).  
1.3.2.1.1 Side effects of natalizumab therapy 
Since natalizumab is associated with the risk of reactivation of latent John Cunningham virus 
(JCV) infection and thereby the development of progressive multifocal leukoencephalopathy 
(PML) it is often used only as a second-line treatment (177). PML is a disease of the CNS 
characterized by demyelination, oligodendrocytes with enlarged nuclei, and enlarged 
astrocytes (178). Infection with JCV is considered a prerequisite necessary to develop PML but 
not the only factor. Around 50% to 60% of people with MS and the healthy population are 
asymptomatic carriers of the JCV (179). There are three risk factors associated with PML 
during natalizumab treatment: 1) presence of serum anti-JCV antibodies, 2) previous use of 
immunosuppressive drugs (including IFNβ), and 3) use of natalizumab exceeding 24 months. 
The estimated risk to get PML has reached 4 per 1000 patients treated (180). A recent meta-
analysis showed that JCV sero-positive patients with a low index value of anti-JCV antibodies 
sometimes revert to a sero-negative status in contrast to JCV sero-positive patients with a 
high index value of anti-JCV antibodies that almost never revert. Moreover, also a conversion 
from sero-negative to sero-positive occurred at a rate of 10.8% per year (181).  
Other adverse events related to natalizumab treatment includes infusion- and 
hypersensitivity reactions. For infusion related reactions such as headaches, it has been 
shown to occur in 24% of the patients receiving the drug compared to 18% of the placebo 
group (170). Hypersensitivity reactions occurred in 4% of the patients receiving natalizumab, 
compared to 0% of the placebo patients (170). 
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1.3.3 Therapies for rheumatoid arthritis 
Disease-modifying anti-rheumatic drugs (DMARD) are the first-line therapy in RA, in 
combination with methotrexate (MTX) as the main drug if the patients have no 
contraindications (182). About one-third of patients respond well to MTX (183) and the vast 
majority of those who respond well to MTX tend to have a better disease course (184). 
However, although this form of treatment is quite effective in reducing the disease symptoms, 
two-thirds of patients do not respond sufficiently and continue to develop joint destruction. 
Biological therapy has revolutionized the outcome of RA during the last 15 years, where the 
TNF-α inhibitors were the first on the market and currently the second-line therapy of choice. 
TNF-α is an inflammatory cytokine known to have a role in the joint damage and TNF-α 
inhibitors effectively inhibits joint destruction (185). Today there are five different TNF-α 
inhibitors approved for the treatment of RA: infliximab (Remicade®), adalimumab (Humira®), 
etanercept (Enbrel®), certolizumab pegol (Cimzia®), and golimumab (Simponi®).  
Infliximab (IFX) was the first TNF-α inhibitor on the market and is currently favored on cost-
effectiveness grounds and for practical reasons including intravenous administration, which 
improves patient compliance. This, and the fact that it can induce immunogenicity, is the 
reason for it being the agent studied in the current thesis.  
1.3.4 Product properties of infliximab 
IFX was the first biologic drug that was shown to be effective for treatment of RA (186). IFX is 
a chimeric mouse-human monoclonal IgG1 antibody, where the variable region is from a 
murine origin and the Fc part (constant domain) is humanized (Fig. 10). There are now several 
IFX biosimilars on or about to reach the market, the first sold under the trademarks Remsima® 
and Inflectra® (with the same substance). Biosimilars have the same formulation as the 
generic drug and similar chemical properties, but since it is a biological substance there can, 
theoretically, be subtle differences. Therefore separate trials were needed to compare those 
to the original IFX and they were found to have equivalent treatment efficacy in RA patients 
(187, 188). IFX is administered intravenously every 4 to 8 weeks with a half-life of 8 to 10 days 
and is detectable in plasma up to 12 weeks after the latest dose.  
 
 
 
 
 
Fig. 10. IFX is a chimeric mouse-human monoclonal antibody. 
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1.3.4.1.1 Mechanism of action 
RA patients have elevated concentrations of TNF- in the joints and this correlates with 
increased disease activity. TNF-α is a pleiotropic pro-inflammatory cytokine that affects 
various cell types. There are two forms of TNF-α; transmembrane bound TNF-α and soluble 
TNF-α. Transmembrane TNF-α is mainly produced by activated macrophages and 
lymphocytes and is a precursor of the soluble TNF-α as depicted in the simplified illustration 
below (Fig. 11). The TNF-α converting enzyme (TACE) cleaves biologically active soluble TNF-
α from transmembrane pro-TNF-α and exerts its biological function through binding to TNF-
α receptor-1 and receptor-2, which are present on almost all nucleated cells (189). 
Transmembrane TNF-α exercises its biological activity through cell-to-cell contact, whereas 
soluble TNF-α can act at remote sites from the TNF-α-producing cells (190). Binding of 
transmembrane and soluble TNF-α to the TNF-α receptors mediates pleiotropic effects 
including apoptosis, cell proliferation and cytokine production (190), which all promote 
inflammation (191). 
Treatment with IFX controls inflammation by high-affinity neutralization of both soluble and 
transmembrane bound TNF-α (Fig. 12; adapted by permission from Macmillan Publishers Ltd: 
Nature (192), copyright 2010). Neutralization prevents TNF-α from binding to the cellular 
receptors and thereby inhibits the bioactivity of TNF-α and the induction of activated T cells. 
Fig. 7. Transmembrane bound TNF-α and soluble 
TNF-α. 
Fig. 11. Transmembrane bound (tm) TNF-α and 
soluble (s) TNF-α. 
Fig. 12. Soluble TNF-α blockade with IFX, Macmillan Publishers. 
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By controlling TNF-α, IFX hinders inflammatory cells from infiltrating inflamed areas of the 
joints (190). Concomitant administration of MTX sustain serum IFX concentrations for longer 
and combination therapy is thus recommended instead of monotherapy (193), both to 
diminish immunogenicity and reduce joint damage (194). 
1.3.4.1.2 Dose optimization 
Treatment with TNF-α inhibitors are not effective in all RA patients. Around 30% of RA 
patients treated with TNF-α inhibitors have a primary response failure (194) and only one-
third have a good response according to the recommended EULAR response criteria. An even 
greater proportion of patients experience secondary failure, as seen with a loss of efficacy 
(secondary response failure) (195). To achieve optimal treatment efficacy with TNF-α 
inhibitors dose optimization strategies can be applied, although currently there are no general 
guidelines with recommendations (196). Both the US and European labeling of IFX 
recommends a dose of 3 mg/kg every 8 weeks. However, the suggested dose for non-
responders differs between US and Europe, where US labeling suggests an increased dose up 
to 10 mg/kg as often as every 4 weeks, but the European guidelines recommend a maximum 
IFX dose of 7.5 mg/kg every 8 weeks or 3 mg/kg every 4 weeks (197).  
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1.4 IMMUNOGENICITY OF BIOPHARMACEUTICALS 
1.4.1 Anti-drug antibody formation 
Prolonged administration of biopharmaceuticals can have an immunogenic effect in the form 
of anti-drug antibody (ADA) formation in treated patients. ADA can be either non-neutralizing 
or neutralizing (198, 199). In 2015 a paper was published as part of the Anti-
Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the 
RISK (ABIRISK) consortium with the aim to standardize definitions related to immunogenicity 
(200). Binding anti-drug antibodies (BAb) and ADA includes all antibodies, regardless of their 
function, that bind to the biopharmaceutical drug and ADA was decided to be the preferred 
acronym. Neutralizing anti-drug antibodies (NAb) are antibodies that reduce or abrogate the 
biological functions of the therapeutic and cause loss of product efficacy with treatment 
failure as a consequence (201, 202). Factors by which ADA/NAb contributes to low or 
undetectable drug levels include drug neutralization or by formation of immune complexes 
that promote the clearance of the drug (Fig. 13). 
Immune reactions to biopharmaceuticals occur when an antigen from the drug is presented 
together with a danger signal to T cells, which in turn activate B cells that will differentiate 
into antibody secreting B cells (203, 204). Even biopharmaceuticals that are almost identical 
to the native human proteins can induce ADA. 
1.4.2 Antibody structure and function 
Antibody molecules are Y-shaped proteins that consist of two fragments of antigen binding 
(Fab) regions and an Fc region (Fig. 14). The Fab region is composed of two pairs of light chains 
that pair up with the two heavy chains, and the Fc part contains the constant region of the 
heavy chains. The Fab region is responsible for antigen binding and has variable domains to 
recognize a diverse repertoire of pathogens. The idiotype is part of the variable region and 
has a unique binding specificity for each antibody clone, i.e. mAb produced by the same B cell 
clone. The Fc part mediates the effector functions such as antibody dependent cellular 
cytotoxicity, phagocytosis, and degranulation. When an immune response is initiated, IgM 
and IgD antibodies are the first antibody isotypes to be produced. Immunoglobulin class 
switching occurs when activated B cells encounter new specific stimulation. Alteration of the 
IgM constant heavy chain, or Fc part, allows class switching into another immunoglobulin such 
Fig. 13. The serum drug concentration inversely 
correlates with the ADA titer. 
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as IgG, IgE and IgA. IgA consists of two subclasses (IgA1 and IgA2) and IgG can be divided into 
four subclasses (IgG1, IgG2, IgG3, and IgG4). Each antibody class and subclass shapes a 
different antibody response to efficiently clear off different pathogens.  
 
1.4.3 Anti-drug antibody development 
There are different factors associated with the immunogenicity of biopharmaceuticals that 
can be classified into the following three categories; i) product ii) patient and iii) treatment 
properties (116, 205, 206). In short, i) product associated factors that can influence 
immunogenicity includes the molecular properties of the drug such as glycosylation and half-
life. Other product-related factors such as the presence of impurities and aggregates and that 
can occur during the manufacturing process can also contribute to immunogenicity. ii) 
Examples of patient-related risk factors include disease state and polymorphisms in HLA 
(207), which can affect the T cell responses (208). Epidemiologic studies have identified that 
smoking increases the risk of developing ADA in MS (209, 210). However, in a study by Auer 
and colleagues where they measured the nicotine metabolite cotinine in the serum from MS 
patients on IFNβ treatment, they found smoking not to be associated with increased risk of 
developing NAb (211). iii) Treatment-associated factors include the treatment duration, 
frequency of administration, and the route of administration (212). The risk of developing 
NAb increases with prolonged duration of treatment and thereby with increased exposure. 
Increased incidence of NAb also occurs if the drug is administered s.c. or i.m. in comparison 
to intravenous administration of the drug.  
1.4.4 Immunological mechanisms involved in immunogenicity  
Theoretically, most protein therapeutics will be able to trigger an immune reaction, which 
leads to antibody formation. Based on the trigger, low-titer, low-affinity, transient IgM 
antibody responses or high-titer, high-affinity IgG responses can be induced. Thus, the causes 
Fig. 14. Antibody structure. 
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of immunogenicity of protein therapeutics are complex and the generation of antibodies to 
therapeutics are multifactorial (213). 
A recent paper by Kalluri and colleagues studied the T cell responses to recombinant IFNβ and 
showed that NAb development was associated to IFNβ specific T cells in treated MS patients 
(208). They found that, despite all patients displaying T cell responses to IFNβ, NAb positive 
patients had a higher frequency of T cell responses compared to the NAb negative patients 
and untreated controls (208). They further identified two IFNβ immunodominant regions. The 
T cell responses to the region located at IFNβ1-40 were observed in all IFNβ treated patients 
regardless of NAb status, whereas region IFNβ125-159 was stronger in the NAb positive patients 
compared to those with a NAb negative state (208). 
1.4.4.1 T cell dependent pathway  
ADA are mainly of the IgG isotype, which suggests a T cell dependent pathway as class 
switching requires T helper cell interaction. Two steps are necessary for the naïve B cell to 
become activated and differentiate into an antibody secreting plasma cell. Firstly, the naïve B 
cell receives primary activating signals when it binds the antigen to it’s B-cell receptor 
(membrane bound Abs), mediates antigen endocytosis and processes the antigen into 
peptides. These peptides are presented on the HLA class II molecules on the cell surface. 
Secondly, T cells with a receptor specific for the presented peptides from the antigen will 
interact with the activated B cell and give the signals required for class switching. The 
interaction occurs via B7 on B cells that binds to CD28 on T cells. The contact between the B- 
and T cell leads to upregulation of the costimulatory molecule CD40 ligand on the surface of 
T helper cells and secretion of B cell stimulatory cytokines by the T helper cells. When the 
costimulatory molecule CD40 ligand on the T cell surface binds to CD40 on the B cell surface 
this instructs the B cells to switch from IgM and IgD production to a downstream antibody 
class on the Ig gene. The cytokines further activate the B cell and stimulate the differentiation 
of B cells into antibody secreting plasma cells. Some of the activated B cells differentiate into 
memory cells with the capacity to react rapidly to re-challenge of the specific antigen by 
production of short-lived plasma cells. T cell dependent antibody responses are generally long 
lasting and of high titers.  
1.4.4.1.1 Affinity maturation 
The process of affinity maturation allows the antigen binding site of the antibody to develop 
a higher affinity for the antigen through somatic hypermutation and selection in the germinal 
center (214). In the rapidly proliferating B cell, affinity maturation occurs randomly within the 
DNA that codes for antigen binding region (heavy and light chain) of the antibodies that are 
produced. The mutations will generate antibodies with different affinities for the same 
antigen and only B cells producing antibodies with the highest affinity will survive the 
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selection in the affinity maturation process, resulting in high affinity antibodies being 
generated. 
1.4.4.2 T cell-independent pathway  
In the T cell-independent antibody responses naïve B cells can be activated by large 
carbohydrates that are constructed with a backbone that contain multiple antigenic 
determinants. If the carbohydrate backbone binds to the naïve B cells IgM and IgD receptors, 
expressed on the cell surface, it forces a strong clustering and crosslinking of the 
immunoglobulins and the signal promotes B cell activation with production and release of low 
titers of IgM and IgD. However, as no T cells are involved there will be no class switching and 
the antibodies are in some instances transient.  
1.4.4.3 The human skin 
As administration routes of biopharmaceuticals have been suggested to influence the risk for 
an immunological response in form of ADA (206, 215), the immunological matrix composition 
and immune cells in the skin are of interest to study. The skin is the human body´s largest 
organ and harbors a complex structure to protect against antigen entry (216). Epidermis and 
dermis are the two main segments of the skin (Fig. 15). The outer layer of the skin consists of 
the epidermis which is abundant of keratinocytes (217) and provides a physical barrier 
between the body and the outer environment by resisting penetration by microorganisms. 
The epidermis is separated from the dermis by a basement membrane which prevents 
interaction between the cells in the epidermis and dermis. An injury to the membrane can, 
however, allow the epidermal cells to come in direct contact with the dermis. The dermis is 
the inner layer formed of collagenous connective tissue and blood vessels. This layer provides 
nutrients and structural support to the epidermis (216). The adipose tissue, which is the s.c. 
fatty region below the dermis functions as the insulation for the body (218). 
 
 
 
 
 
 
 
Epidermis 
Dermis 
Fig. 15. Epidermis and dermis are the main 
segments of the skin.  
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1.4.4.3.1 Immunity in the skin 
Other than acting as a physical barrier, the skin provides an immunological barrier to the 
external environment. There is a constant interplay between keratinocytes, immune cells, 
and microorganisms in response to wounding and infection. The immune system is initiated 
by recognition of pathogen-associated molecular patterns that activate keratinocyte pattern 
recognition receptors, resulting in the secretion of antimicrobial peptides, cytokines, and 
chemokines (216, 219, 220). The cytokines initiate effector mechanisms (221), whereas the 
chemokines recruit T cells and innate effector cells such as monocytes to the skin (222). In 
addition to keratinocytes the epidermis contains memory T cells, Langerhans cells (LC), 
Merkel cells, and melanocytes. The dermis is composed of elastin- and collagen fibers and a 
matrix produced mainly by fibroblasts (223). The cell types that contribute to immune 
function in dermis are mast cells, macrophages, dendritic cell (DC) subsets, innate lymphoid 
cells and T cells (223). Healthy human skin contains a large population of resident-memory T 
cells, which are believed to be non-recirculating T cells which mediate protective immunity in 
the skin. Nearly all of these T cells have the skin homing receptor cutaneous leucocyte-
associated antigen that enable binding to E-selectin expressed on cutaneous blood vessels 
(7). Healthy skin contains as much as 1 × 106 T cells/cm2, and thus almost twice the number 
compared to the T cells in circulation (8). 
1.4.4.3.2 Skin resident DC  
DC are critical regulators for the control of immunity and tolerance and they are present 
throughout the body. The DC system is composed of a variety of subsets exerting different 
types of immunity (224). DC subsets can circulate the blood, reside in the lymphoid organs or 
the peripheral tissues. In the peripheral tissue DC capture antigens and then migrate to the 
lymph nodes and present antigens both directly to T cells via HLA class I and II, and also 
through the non-classical CD1 antigen presenting molecule (225). Human skin contains at 
least two myeloid DC subtypes: epidermal LC and dermal DC. The dermal DC can be divided 
into at least two subsets: CD1a+ DC and CD14+ DC. Since antibody responses are suggested to 
be mediated by CD14+ dermal DC (226), it has been proposed that CD14+ DC would be a 
suitable target to induce a potent humoral immune response in vaccination (227, 228). This 
hypothesis is supported by mouse studies which show that activated dermal DC migrate 
towards B cell follicles, whereas activated LC migrate to the T cell paracortex in the cutaneous 
lymph node (229). The cellular mechanism behind regulation of immunity at the skin site has 
been shown by Klechevsky and colleagues (230). They found that CD14+ DC induced 
differentiation of naïve T cells into T follicular helper cells, which in turn regulate humoral 
immunity (231). Thus, CD14+ DC prime CD4+ T cells to induce B cells which in turn produce 
larger amounts of IgM than those B cells induced by CD4+ T cells primed with LC. Moreover, 
they showed that CD4+ T cells could induce naïve B cells to an Ig class switch toward IgG and 
IgA (230), and these findings were supported by another study (232). Based on this notion 
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they suggested that targeting CD14+ dermal DC could potentially induce an enhanced 
antibody response. Data have also showed that LC, expressing marker CD207+, could 
stimulate T cells to become T follicular helper cells (233). LC can furthermore activate T cells 
to become efficient helpers for the activation of cytotoxic T lymphocyte responses (230, 234, 
235) (Fig. 16, adapted with permission from Drug discovery today (235), copyright 2011). 
 
 
 
 
 
 
 
 
 
1.4.5 Occurrence of anti-drug antibodies  
1.4.5.1 Interferon beta immunogenicity 
ADA occur in nearly all the IFNβ treated patients (236) and up to half of them will become 
NAb positive (215). NAb generally develop between 6 to 18 months after therapy initiation 
(237). For the IFNβ treated MS patients there are different rates of immunogenicity for each 
preparation, where IFNβ-1a (i.m.) and IFNβ-1a (s.c.) are less immunogenic than IFNβ-1b (s.c.) 
(Table I) (123, 238). NAb against IFNβ-1a occur at a lower incidence but often generate higher 
NAb titers which often persist, while NAb to IFNβ-1b occur more frequently but are of lower 
titers and can be transient (239). The most recently approved IFNβ-1a formulation (Plegridy®) 
was found to have a very low immunogenicity with less than 1% that became NAb positive 
during a follow-up period of two years (240). 
1.4.5.2 Natalizumab immunogenicity 
ADA against natalizumab have been found in up to 9% of the treated patients (241) and can 
be detected as early as three months after treatment initiation (Table I) (242). These 
antibodies can be either confirmed persistent or transiently positive (241, 243, 244), where 
half of the ADA positive group are transient (241). In persistently positive patients, 
significantly higher ADA levels can be detected compared to the transiently positive. 
Fig. 16. Skin immunity, Drug discovery today. 
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Moreover, the level of total ADA in the first sample can be used to predict patients at risk for 
being persistently ADA positive (242). 
 
1.4.5.3 TNF-α inhibitor immunogenicity 
Several studies have shown that ADA reduce the bioavailability of the targeted TNF-α inhibitor 
in the circulation of the treated RA patients (245-249), and this in turn is associated with 
failure to respond to the drug (250-252). ADA negative patients usually display normal to high 
serum drug trough levels in contrast to ADA positive patients that have very low or 
undetectable serum drug trough levels (249, 253, 254). The frequency of ADA positivity varies 
significantly between studies and can be a result of different factors such as the patients’ 
concurrent medications, the timing of sampling, and which bioassay used for ADA detection 
(255, 256). Furthermore, ADA binding to the therapeutic can result in immune complex 
formation and become undetectable using standard laboratory techniques (257). Acid 
dissociation assays are used to overcome immune complex formation as these assays can 
dissociate any drug and ADA complexes (258).  
ADA development is reported in up to 44 percent of patients treated with adalimumab (247, 
259, 260) and in up to 17% of the patients treated with IFX (261), but concomitant 
immunosuppressant treatment with MTX is suggested to reduce ADA development (262). 
ADA to etanercept has been reported (260), whereas other studies have been unable to 
detect any ADA (263).  
1.4.6 Clinical relevance of anti-drug antibodies  
1.4.6.1 Multiple sclerosis 
The clinical significance of NAb is sometimes difficult to assess in MS as many studies have a 
short follow-up time (less than two years), resulting in the late appearing NAb and the time it 
would take for the NAb to exert clinical relevance, not being accounted for (264). However, 
several studies confirm that NAb positive MS patients treated with IFNβ have increased 
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disease activity relative to NAb negative patients (137, 265, 266). For example, in a pivotal 
trial on IFNβ-1b, the NAb positive group had a relapse rate during years 2 and 3 that was 
higher than for the NAb negative group (267). Furthermore, another study found that IFNβ 
NAb positive patients had higher annual relapse rates than ADA negative patient during 
years 3 and 4 (268), and a large Danish study saw the same phenomenon after 42 and 48 
months of treatment (269). In addition, IFNβ NAb positive patients have been shown to have 
more gadolinium (radiocontrast agent) enhancing lesions on MRI compared to NAb negative 
patients (270). To overcome immunogenicity of IFNβ protein modifications to eliminate 
aggregation-prone regions and epitopes by point mutation are implemented during the drug 
development process (116).  
For anti-natalizumab antibodies, studies have shown that persistent antibody positivity 
resulted in low natalizumab levels and induced infusion-related adverse events, including 
hypersensitivity reactions (170, 241). Furthermore, Vennegoor and colleagues showed that 
antibodies that persist are associated with increased occurrence of relapses and brain lesions 
(271). An additional study by Vennegoor and colleagues showed that MS patient with high 
antibody titers to natalizumab had very low or undetectable concentrations of natalizumab 
and was associated with relapses and gadolinium enhanced lesions on MRI (271).  
1.4.6.2 Rheumatoid arthritis 
For ADA to TNF-α inhibitors, a study by Pascual-Salcedo et al. showed that anti-IFX antibodies 
were associated to loss of clinical response (245). A meta-analysis by Garces and colleagues 
showed that ADA to TNF-α inhibitors significantly decreased the drug response rates (272). 
Moreover, for IFX treated patients, immune complexes can form between the therapeutic 
and ADA. Depending on the form, size and interaction of the immune complexes, adverse 
events such as hypersensitivity reactions (255, 273) and IgE-mediated anaphylaxis can occur 
in a proportion of patients receiving IFX (274). In addition, the circulation of immune 
complexes in the bloodstream results in lysosomal degradation of the immune complexes and 
this phenomenon becomes an additional factor that contributes to that the protein might be 
cleared from the body before it can elicit its therapeutic effect. Risk factors for the formation 
of immune complexes have been identified and are based on the therapeutics molecular 
constitution, route of delivery, and binding to HLA alleles.  
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1.5 ASSESSMENT OF IMMUNOGENICITY  
Depending on the biopharmaceutical drug used for treatment different strategies for 
ADA/NAb detection can be undertaken. Since IFNβ is a cytokine, and thus has a short half-
life, the serum samples are screened for the presence of NAb instead of measuring the drug 
level that often is implemented for mAb therapy. The NAb positive samples are thereafter 
titrated as a confirmatory step to validate the positive result. For RA patients on mAb 
treatment such as TNF-α inhibitors, the drug concentration in trough level can indicate 
whether ADA testing is needed. If the drug level is low, the sample is screened for the 
presence of ADA followed by titration as a confirmatory step. It is recommended to retrieve 
the patient’s serum sample just before the next dose (trough) to avoid drug interference. 
Measuring the immunogenicity of biopharmaceuticals can be done using various methods 
including:  
 Enzyme-linked immunosorbent assays (ELISA) that determine the presence of all 
antibodies but cannot separate binding from neutralizing; 
 Radioimmunoassay (RIA) uses radioactively labeled drug to detect ADA; 
 Cell-based bioassays that identify the presence of NAbs; and  
 Electrochemiluminescent (ECL) immunoassays using Meso Scale Discovery technology 
that have the advantage of not being drug sensitive (when using acid disociation) and 
identifies both free and bound ADA (immune complexes).  
1.5.1 ELISA  
ELISA is a commonly used screening assay for detection of ADA. Compared to cell-based 
assays ELISA are both easy to design and perform and thus have the advantage of allowing 
high throughput screening. Different assay formats that may be used include direct, indirect, 
and bridging ELISA. The bridging assay has high specificity, since the ADA is recognized twice; 
first by the solid-phase-bound antigen and then by visualization by the labeled antigen (Fig. 
17).  
Fig. 17. Detection of ADA using a bridging ELISA. 
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The bridging ELISA is therefore often favored over the other assay formats. However, there 
are disadvantages with the bridging assay format since it detects disease-specific antibodies, 
such as RF that can bind to the drug causing interference (275). Direct ELISA, however, is even 
more prone to RF interference (87). Interference is an issue as it can confounds detection and 
interpretation of treatment-induced ADA (275). Moreover, the bridging assays cannot 
identify the IgG4 isotype (e.g. antibodies of the IgG4 subclass undergoing Fab arm exchange) 
(276), which can lead to false negative results.  
1.5.2 Radioimmunoassay  
Classically, the assay is performed where the target antigen is radioactively labeled and is 
based on competitive-binding between the radiolabeled antigen and an unlabeled antigen to 
a high affinity antibody. The method is more sensitive than the bridging ELISA and has also 
the advantage of identifying the IgG4 subclass (251). However, since RIA requires use of 
radioactive materials it is limited to be performed in specialized laboratory facilities. 
1.5.3 Cell-based bioassays  
Assays used to measure NAb are based on the antibodies ability to antagonize the 
biopharmaceutical in for example the cellular response of the drug. Numerous assay systems 
have been developed to measure NAb to IFNβ including the cytopathic effect assay where the 
cells are challenged with virus or the MxA gene expression assay where the receptor-specific 
signals are quantified by the reduction of the IFNβ-induced genes such as MxA expression at 
mRNA or protein level (277-279). The presence of IFNβ strongly and specifically induces the 
expression of MxA and this response is affected in a NAb titer dependent manner, where high 
titer NAb abrogate the expression and low titer NAb lower the expression (280, 281). Another 
readout for NAb detection is the use of cells transfected with a firefly luciferase reporter-gene 
to quantify drug activity (iLite).  
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1.5.3.1 NAb positive/negative to IFNβ therapy 
In the illustration below (Fig. 18), NAb to IFNβ is analyzed using the iLite IFNβ bioassay. If no 
NAb are present in the sample, the added IFNβ will stimulate the interferon receptor and thus 
generate a high luminescence signal (Fig. 18A). If NAb are present in the patient´s sera, they 
will interfere with the biopharmaceutical, resulting in a low luminescence signal (Fig. 18B). 
For the calculations of NAb titers the Kawade method has often been used and the titer is 
defined as the value of the dilution of serum that gives a ten-fold reduction of IFNβ bioactivity 
and is expressed in ten-fold reduction units (TRU/mL) (282).  
 
1.5.3.2 Potential interference in immunoassays 
When serum samples are tested for immunogenicity using bioassays, there are potential 
interference problems that one should be aware of including immune complex formation 
between the NAb and the drug (273). Thus it is possible to obtain false negative results as 
many assays cannot measure NAb/drug complexes (283). Immune complexes can for 
example occur when the patient is treated with mAb drugs such as IFX. In the illustrations 
below (Fig. 19, 20, 21), NAb to IFX is analyzed using the iLite IFX bioassay.  
Fig. 18. Measure NAb to IFNβ in a cell based assay. (A) No NAb present 
versus; (B) NAb present in the patient sample. 
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1.5.3.2.1 NAb negative 
For analysis of serum samples that are NAb negative, the added IFX (Fig. 19-1) will be free to 
bind the added TNF-α (Fig. 19-2). Subsequently the TNF-α will not bind to the TNF-α receptor, 
resulting in failure to induce transcription and consequently no luminescence signal will be 
generated (Fig. 19-3). An undetectable signal will result in a NAb negative readout.  
1.5.3.2.2 NAb positive 
The illustration below depicts screening of a NAb positive sample without drug interference 
(Fig. 20). NAb is present in the serum sample (Fig. 20-1), the added IFX will be bound to the 
NAb (Fig. 20-2). When TNF-α is added there will be no free IFX available and subsequently 
TNF-α will bind to the TNF-α receptor resulting in receptor-induced activation of luciferase 
synthesis and an enhanced luminescence signal (Fig. 20-3). A high signal will indicate the 
presence of NAb in the patient’s serum sample.  
 
 
 
 
 
 
 
Fig. 20. Measure NAb to mAb without drug inference using a cell based assay. 
Fig. 19. Measure NAb to mAb using a cell based assay. 
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1.5.3.2.3 Drug/NAb immune complexes 
The illustration below depicts screening of a NAb positive sample with drug interference (Fig. 
21). NAb positivity can be masked because of the presence of drug/NAb immune complexes. 
If IFX and NAb (both present in the patient´s serum) forms immune complexes the added IFX 
will be outcompeted (Fig. 21-1). The added IFX is therefore free to attach to the added TNF-α 
(Fig. 21-2). No TNF-α is available to bind to the cell receptor and thus no luciferase activity is 
detected and the sample is falsely identified as NAb negative (Fig. 21-3).  
1.5.4 ECL assays on the Meso Scale Discovery platform 
Both ELISAs and the cell-based assay have the disadvantage of being sensitive to a 
circulating drug that may interfere with ADA detection and the presence of ADA may 
interfere with quantification of drug levels. Thus, when assessing ADA, it is essential that 
the patient sample is retrieved at a time point when the drug level is as low as possible, that 
is at trough level. A strict sampling window is particularly important when the patient is on 
mAb treatment as they have a long half-life compared to protein drugs such as IFNβ. 
Moreover, if the patient has ADA, it could lead to immune complexes between the ADA and 
the drug, which may interfere with ADA assessment in immunogenicity assays, as already 
described. Zoghbi and colleagues recently developed a method under the MSD technology 
platform called Precipitation and Acid dissociation assay (PandA) (Fig. 22), that effectively 
solves the drug interference problems based on the following four steps (258):  
1. Excess of the drug is added to the serum sample to cause saturation of ADA and 
thereby allows the formation of drug/ADA complexes;  
2. Complexes containing ADA are precipitated using polyethylene glycol (PEG); 
3. The precipitate is coated in an acidic solution on a high binding carbon plate with 
the ability to dissolve the immune complexes and prevent reformation of drug/ADA 
complexes; and  
Fig. 21. Measure NAb to mAb 
encountering drug inference 
using a cell based assay. 
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4. Total ADA levels are detected using a SULFO-TAG that is conjugated to the drug 
allowing an ECL signal that is comparative to the amount of ADA in the serum 
sample. 
 
By performing these four steps, complete recovery of ADA can be obtained regardless of 
the presence of drug or immune complexes in the sample (258). 
1.5.5 Assay validation essential for quality assurance 
As there are a range of bioassays available to measure ADA, there can be variations in both 
the assay used and the method of data reporting between testing laboratories. 
Immunogenicity of biologic drugs can affect both safety and efficacy of the treatment course, 
and suitable immunoassays that can measure ADA with a high precision are thus a necessary 
step to consider even during drug development. The increased use of biopharmaceuticals 
have resulted in a requirement of drug developers to provide an immunoassay, for every new 
drug, and measure ADA according to the current regulatory authority guidelines (284, 285). 
Guidelines on how to perform bioassay immunogenicity testing and data presentation have 
been published and updated on several occasions (284, 286, 287). Shankar and colleagues 
suggest that validation of ADA methods according to their recommendations offer the 
conclusive characterization of samples into ADA-positive versus ADA-negative and that would 
lead to fewer ADA-inconclusive samples (284). Important factors to consider are serum matrix 
effects and the use of a statistically based cut-point approach. These recommendations was 
recently updated by Devanarayan et al. (288). In conclusion, even though the use of validated 
immunoassays that comply with regulatory authority requirements result in increased assay 
sensitivity the clinical relevance of these modifications needs to be determined. 
Fig. 22. Detection of ADA in the ECL assay. 
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2 AIMS OF THESIS 
The overall aims of my Ph.D. projects were to characterize the immune response against 
biopharmaceuticals and evaluate the clinical relevance of drug levels and ADA/NAb in people 
with MS and RA.  
During my Ph.D. the focus of my research has been to: 
[Paper 1 and 2] investigate how IFNβ treatment affects endogenous immune 
processes and how these are blocked by NAb and evaluate 
laboratory methods used to monitor immunogenicity. 
[Paper 3]  validate a cell-based bioassay using a cut-point approach to 
identify NAb to IFNβ. 
[Paper 4]  monitor TNF-α-inhibitor drug levels and free and bound ADA 
to TNF-α-inhibitors. 
[Paper 5] evaluate immune responses against IFNβ at the injection site. 
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3 MATERIAL AND METHODS 
For a more detailed description of the methodology, see the individual methods section for 
each research paper. 
All studies were approved by the regional ethical board in Stockholm, Sweden. 
3.1 STUDY I AND II 
Study I - Interferon beta treatment of multiple sclerosis increases serum interleukin-7. 
Study II - Anti-interferon beta antibody titers strongly correlate between two bioassays and 
in vivo biomarker expression, and indicates that a titer of 150 TRU/ml is a biologically 
functional cut-point. 
3.1.1 Human serum samples 
In study I and study II, people with MS on IFNβ treatment previously analyzed for NAb in our 
routine NAb core at Karolinska Institutet were included. Study I included 184 MS treated 
patients from all over Sweden. Study II included 44 MS patients treated at four Swedish 
neurological hospitals including Karolinska Institutet Solna and Huddinge (Stockholm), 
Danderyds hospital (Stockholm), and Sahlgrenska hospital (Gothenburg). The recruitment 
lasted for three years (2010-2013) for study II and the inclusion criteria were based on that 
they should be between 18 to 60 years of age, diagnosed with MS, and being treated with any 
of the four IFNβ preparations Avonex®, Rebif®, Betaferon®, and Extavia®. All patients signed 
a consent form. Peripheral blood was collected for gene expression- and NAb analysis.  
3.1.2 NAb analysis 
To measure the presence and titer levels of NAb, MGA was used in study I, and MGA and iLite 
were used in parallel in study II. MGA was used in our clinical routine lab for several years and 
as iLite was newly implemented on the market we wanted to run them in parallel in order to 
establish whether we could use iLite instead of MGA. iLite has a simplified way to measure 
NAb with shorter incubation steps and by not requiring cell culture since it has frozen growth-
arrested cells ready to use. 
In the MGA assay the patient serum was pre-incubated with IFNβ-1a before addition of the 
suspension to the cell line A549 (human embryonic lung cells). After incubation the cells were 
lysed and RNA was extracted and converted to cDNA. The ability of the patients’ serum to 
neutralize IFNβ-induced MX1 was quantified by real-time PCR (TaqMan).  
In iLite the protocol was carried out according to the manufacturers’ instructions 
(Biomonitor). In short, division-arrested cells carrying the luciferase reporter gene under the 
control of an IFN-responsive promoter were used. Transcription of the luciferase gene occurs 
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when the IFNβ molecule binds to the type I IFN receptor. Luciferase activity was measured 
using GloMax 96 Microplate Luminometer by relative luminescence units (RLU).  
3.1.2.1 Calculations of NAb titers 
To calculate the NAb titer the neutralizing activity of the patient’s serum sample were 
adjusted according to the Kawade method using Softmax Pro software for MGA and Microsoft 
Excel software for iLite. Results from our bioassays were calculated according to the formula: 
  
𝑡 = 𝑓
(𝑛 − 1)
(10 − 1)
 
Where t is the NAb titer, f is the dilution of the patient serum at endpoint (1 international unit 
/mL), and n is the amount of added IFNβ. The NAb titers were expressed as 10-fold reduction 
units per milliliter (TRU/mL) and the patients were classified according to the following four 
categories (as used in the routine setting):  
i. Negative ( <10 TRU/mL) 
ii. Low positive (10 - 50 TRU/mL) 
iii. Medium positive (>50 - 200 TRU/mL) 
iv. High positive (>200 TRU/mL) 
A titer of >150 TRU/mL was used as a cut-point for a clinically relevant titer (289). 
3.1.3 Flow cytometry 
For study I, flow cytometry was performed to investigate the cellular expression of IL-7Rα on 
PBMC incubated with IFNβ and IL-7 or with only IL-7. Cells were kept at 4℃ throughout the 
laboratory procedure supplemented with fetal calf serum during antibody staining.  
3.1.4 Gene expression 
cDNA was synthesized from RNA, and IL-7Rα, MX1, and CXCL10 were quantified by real-time 
PCR and the expression levels of each gene was normalized to the housekeeping gene HPRT1 
(GAPDH – data not shown) using the delta cycle threshold (∆Ct) formula. Ct values were the 
mean of technical duplicates and replicates more than 1 Ct cycle apart were excluded as a 
technical outlier. Each normalized ∆Ct was calibrated against the ∆Ct value from a healthy 
control. Relative gene expression was calculated using the 2∆∆Ct method. 
3.1.5 ELISA 
Serum IL-7 and CXCL10 levels were detected using commercially available ELISA kits. The 
sensitivity of the IL-7 and CXCL10/IP-10 ELISA´s were 0.1 pg/mL and 1.67 pg/mL respectively. 
All samples were run in duplicates.  
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3.1.6 Statistical analysis  
Statistical analysis was performed using GraphPad Prism version 6. For study I, p-values were 
calculated by unpaired two-sided t-tests. The Shapiro-Wilk test was used to verify normal 
distribution of the data. As the data for study II was not normally distributed, we used a 
Spearman non-parametric correlation test to determine the relationship between two 
variables. To establish differences between unpaired and paired groups we used non-
parametric Mann-Whitney and Wilcoxon matched paired test. Statistical significance was 
defined as a p-value below 0.05. 
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3.2 STUDY III 
Development and validation of cell-based luciferase reporter gene assays for measuring 
neutralizing anti-drug antibodies against interferon beta.  
3.2.1 Pre-validation laboratory work 
Pre-validation work of iLite was performed as follows: 
3.2.1.1 Selection of the optimal stimulation concentration of IFNβ  
To establish half of the maximal effective concentration (EC) 50, i.e. 50% of IFNβ maximum 
effect on the cells, dose-response curves were generated (Fig. 23). The dose-response curves 
were defined by four established parameters; first - the baseline response (bottom), secondly 
- the maximum response (top), third - the slope (steepness), and lastly - the drug 
concentration that provokes a response halfway between the baseline and maximum. The 
dose-response curves needed to reach a lower and 
upper plateau. To determine the EC50, two 
operators ran three independent dose-response 
curves on three plates, on three different days. In 
sum, this created 18 independent dose-response 
curves. EC50 was calculated using a 4 parametric 
logistic model (4PL) fit. 
3.2.1.2 Selection of an HPC and LPC 
The selected stimulation concentration of IFNβ (EC50) was used to perform inhibition curves 
with a positive control for IFNβ that reached an 
upper and lower plateau (Fig. 24). Two 
operators ran three independent inhibition 
curves per plate on three different days. In 
sum, this created 18 independent inhibition 
curves that were fitted with 4PL. A preliminary 
high positive control (HPC) and low positive 
control (LPC) were selected in the upper and 
lower linear area of the inhibition curve 
respectively. 
Fig. 23. Dose response curves to 
select the EC50. 
Fig. 24. Inhibition curves to select 
the HPC and LPC. 
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3.2.1.3 Minimum required dilution 
The selected EC50 and high and low positive controls were used to perform the third step; to 
establish the minimum required dilution i.e. the Z-factor (Fig. 25) (290). The Z-factor reflects 
the difference in the size of the signals and the signal variation within both the sample and 
the control i.e. how well the positive signal resolves from the negative signal. On the x-axis 
the sample signal is lower than the control signal since it is an inhibition assay. In the assay, 
assuming the blank has a fixed signal intensity and spread, the Z-factor will increase as the 
sample becomes more NAb positive (i.e. the separation between the sample and blank is 
increased). Z values of 1 are ideal as the separation between the signals is very good. A Z-
factor of between 0.5 and 1 is excellent. If the Z-factor is 0 there is no difference between the 
sample and the blank (290). To calculate the Z-factor dilutions of 6 human serum samples and 
control samples (assay media) were prepared. The samples were spiked with IFNβ alone or 
with IFNβ plus anti-IFNβ to give the selected EC50 IFNβ concentration and anti-IFNβ 
concentrations corresponding to the HPC and LPC.  
 
3.2.2 Validation laboratory work 
3.2.2.1 Serum samples 
To establish the minimum required dilution (MRD), cut-points, and sensitivity, serum samples 
from treatment-naïve MS patients are preferred since patients with autoimmune diseases 
may have higher immune reactivate components in their serum than the overall healthy 
population. Consequently, disease state samples may have components that can cause the 
background signal to vary if compared to healthy serum, and thus the use of healthy serum 
may generate a different cut-point than if the disease state serum samples are used. However, 
we could not retrieve enough disease state samples in this experiment and therefore used 54 
serum samples from healthy individuals.  
Fig. 25. The Z-factor score assess the quality of the assay. 
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3.2.2.2 Cut-point  
To determine the cut-point for iLite and the LUC assay, 54 serum samples from healthy 
controls were tested in duplicates, on three separate days by two operators generating 6 
independent tests for each serum sample. All plates included positive and negative controls 
and the serum samples were subjected to IgG immunodepletion to establish a confirmatory 
cut-point. The linear scale versus the logarithmic scale was evaluated for distribution and 
symmetry for the values generated for each assay run. Next we checked for biological outliers 
using box-plots. Removal of biological outliers is necessary when determining a cut-point 
since these values are not representative of samples from the patient population. If such 
values are not removed they could potentially lead to a very high or very low cut-point and 
thus lead to either false-negative or false-positive samples. Next, analytical outliers were 
removed using box-plots and the samples were characterized by the 25th, 50th and 60th 
percentiles. Analytical outlier refers to when serum from one donor generates significantly 
higher or lower values in one of the runs compared to the other donor samples in the same 
run. Distribution and skewness were assessed for each run to know what method to use to 
calculate the cut-point and specificity cut-point. 
3.2.3 Statistical analysis  
Assay data reflecting variability were expressed in terms of the mean, the sample standard 
deviation, and the coefficient of variation. Curve fitting and statistical analysis were 
performed using Excel software (Microsoft®), XLfit (ID Business Solutions), GraphPad Prism 
version 6 (La Jolla), JMP (SAS Institute Inc.), and SPSS (IBM). For validation work, Shapiro–Wilk, 
one-way ANOVA and Levene's test were used for the cut-point assessment. Spearman 
correlation test was used to assess the relationship between NAb titers. 
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3.3 STUDY IV 
Measurement of serum infliximab levels and detection of free and bound anti-infliximab 
antibodies in patients with rheumatoid arthritis 
3.3.1 Study samples 
This study included RA patients from three cohorts in Sweden; 101 RA patients from the 
SWEFOT cohort (Karolinska University Hospital), and REALlife including 272 patients from 
Stockholm (Karolinska University Hospital) and 42 patients from Gothenburg (Sahlgrenska 
University Hospital).  
3.3.2 ELISA  
The serum level of TNF-α inhibitors and ADA to TNF-α inhibitors were measured with two in-
house developed and validated ELISA (291) used in clinical routine at Karolinska University 
Hospital and at Sahlgrenska University Hospital.  
3.3.2.1 Detection of IFX serum levels  
The level of IFX in a patient´s serum sample is based on the binding of added patient serum 
(containing IFX) to TNF-α-coated ELISA plates. Alkaline phosphatase (ALP)-conjugated IgG (Fc-
specific) antibodies thereafter bind to IFX (if present in the patient’s serum sample). The signal 
generated by the detection antibody reflects the concentration of IFX present in the patients´ 
sample (Fig. 26).  
  
 
Fig. 26. Direct ELISA. 
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3.3.2.2 Detection of antibodies to infliximab 
Inhibition ELISA, also known as competitive ELISA, was used for quantification of ADA levels 
to IFX (Fig. 27). ADA detection is based on the inhibition of binding ALP labeled IFX to TNF-α-
coated ELISA plates. A signal will be generated if no ADA is present in the serum sample (A), 
while a lower signal or no signal will be generated if ADA is present (B). 
3.3.2.3 Free and bound ADA detection with PandA  
Presence of free and bound IFX antibodies was assessed using an in house validated PandA 
method on the Meso Scale Discovery platform. In the assay, added excess of IFX to the serum 
sample cause saturation of ADA and thereby allowing the formation of drug/ADA complexes. 
The complexes containing ADA are precipitated using PEG. Thereafter the precipitate is 
coated in an acidic solution on a high binding carbon plate (high coating capacity), which 
prevents reformation of drug/ADA complexes. The total ADA levels are detected using a 
SULFO-TAG that is conjugated to the drug (IFX) allowing an ECL output. 
3.3.3 Measurement of neutralizing ADA  
The neutralizing capacity of ADA positive serum samples were analyzed using the iLiteTM IFX 
NAb bioassay (Biomonitor). The protocol was carried out according to the manufacturers’ 
instructions. The assay uses cells that are sensitive to TNF-α and can thus measure TNF-α 
bioactivity. In the assay format NAb positivity will be indicated when added TNF-α binds to 
the TNF-α receptor. Luciferase activity was measured using GloMax Luminometer (Promega) 
and the antibodies neutralizing activity was normalized to Renilla. 
Fig. 27. Inhibition ELISA 
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3.3.4 Statistics  
Assay data reflecting variability were expressed in terms of the mean, sample standard 
deviation, and the coefficient of variation. Statistical calculations were performed using Prism 
software (GraphPad Inc. version 6). The data was calculated by linear regression analysis and 
statistical significance was defined as a p-value below 0.05. 
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3.4 STUDY V 
Different interferon beta preparations induce the same qualitative immune response in 
human skin. 
3.4.1 Human skin model  
3.4.1.1 Ex vivo skin model 
Skin was retrieved from patients who underwent 
abdominal plastic surgery. The laboratory procedure 
went as follows: First, the skin was surgically removed 
from the patient and the skin was stored at 4℃. The skin 
tissue was shortly thereafter transported on ice to 
Karolinska Institutet. The laboratory work included 
removal of the adipose tissue with a scalpel, then 
intradermal injections were performed with IFNβ diluted 
in PBS and with PBS alone (Fig. 28). The syringe was 
placed at a 5 to 15 degree angle and the technique was 
applied to get a bollows in the epidermis. The formation 
of a bollow allows easy control that the drug was correctly injected into the dermis. Right 
after the injection a biopsy was sampled and transferred to a tissue plate with cell media. 
Biopsies for the different experiments were collected as follows (Fig. 29); 
From the skin piece, the injection and biopsy collection were performed with a drug 
concentration gradient in mind meaning that the uninjected biopsies were collected first, 
followed by PBS injection and collection. Lastly the lower concentration of IFNβ was injected 
and biopsies collected, followed by the high dose IFNβ. Skin sites that had stretchmarks or 
tattoos were not used. The edge of the skin piece was avoided, allowing at least 2 centimeters 
from the edge to be disregarded.  
Fig. 29. Timeline for the ex vivo biopsy collection. 
 43 
 
3.4.1.2 In vivo skin model 
MS patient biopsies were collected after s.c. IFNβ injection into the abdomen or thigh. A 
control biopsy was collected simultaneously on the opposite side of the body (Fig. 30), and 
the timeline illustrates when the biopsies were sampled (Fig. 31). 
 
 
 
 
 
 
 
3.4.2 Flow cytometry 
 
 
3.4.3 DC phenotyping 
For phenotyping, flow cytometry was performed on migrated skin cells retrieved from 
abdominal reconstructive surgery using the antibodies listed in Table II. Cells were kept at 4℃ 
throughout the laboratory procedure and supplemented with fetal calf serum during 
antibody staining. 
Fig. 30. An example of injection/biopsy 
sampling sites. 
 
Fig. 31. Timeline for the in vivo biopsy collection. 
Table II. Antibodies used to phenotype the dendritic cells by flow cytometry. 
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3.4.4 CD4+ T cells 
Although the cells had been subjected to a one-step 
purification by bead separation, it was not sufficient 
to achieve a pure naïve CD4+ T cell population. As a 
result, the cells were subjected to a second step 
purification using flow cytometry sorting in order to 
obtain a highly purified naïve CD4+ T cell population 
(Fig. 32). To identify the population of naïve CD4+ T 
cells, we examined the expression of CD4+ and 
CD45RA. 
3.4.5 ATPlite 
To evaluate CD4+ T cell proliferation, the ATPlite luminescence assay (PerkinElmer) was used. 
In short, migrated DC were irradiated and cultured with naïve CD4+ T cells and proliferation 
was measured after 5-6 days. As controls, naïve CD4+ T cells and DC were cultured separately.  
3.4.6 Immunohistochemistry 
Immunohistochemistry staining was performed, using the antibodies listed in Table III, on OCT 
embedded skin tissues from abdominal reconstructive surgery or biopsies from MS patient’s 
on IFNβ treatment. Diaminobensidine and hematoxylin were used for staining and 
counterstaining respectively. Appropriate isotype controls were included to determine 
nonspecific binding. The sections were prepared in a way so that the testing condition were 
on the same slide, i.e. for each antibody testing condition the biopsies from the uninjected 
site, PBS injection, and the IFNβ injection (from one donor) were on the same slide. Thus, the 
same condition was implemented for the biopsies and thereby more reliably comparison of 
staining intensity. 
 
3.4.7 Statistical analysis 
Data are presented as the mean, standard deviation, and coefficient of variation. The data 
was not always normally distributed and was therefore analyzed using non-parametric paired 
Wilcoxon test. Statistical calculations were performed with GraphPad Prism 6. Significance 
was defined as a p-value < 0.05.  
Fig. 32. Naïve CD4+ cell sorting. 
Table III. Antibodies used during immunohistochemistry. 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I AND STUDY II 
4.1.1 Background study I 
Outside the HLA region, the IL-7R was the first confirmed gene associated with MS (53-55), 
and a GWAS study identified IL7 as a MS susceptibility gene (50). IL-7 is a non-redundant 
survival cytokine essential for T and B cell development and T cell homeostasis (292). IL-7 is 
mainly produced by stromal and epithelial cells localized in the peripheral tissues (293) 
including the lymph node, skin, and intestine. IL-7 is particularly essential for T cell biology 
and plays a crucial role during the maturation of T cells in the thymus, CD4/CD8 lineage choice 
Study I  
Interferon beta treatment of multiple sclerosis increases serum interleukin-7. 
Hypothesis 
IFNβ therapy has immunomodulatory properties on the endogenous levels of IL-
7 and this effect is important for the treatment efficacy and reduced by NAb. 
Reflections 
Study I provided laboratory experience including establishing cell culture 
conditions, setting up flow cytometry and ELISA. In addition, I learned the 
statistics program GraphPad and other relevant statistical tools.  
 
Study II  
Anti-interferon beta antibody titers strongly correlate between two bioassays and 
in vivo biomarker expression, and indicates that a titer of 150 TRU/ml is a 
biologically functional cut-point. 
Hypothesis 
NAb titers measured with two bioassays, MGA and iLite, give comparable titers 
and the gene expression of IFNβ inducible genes MX1 and CXCL10 are 
significantly reduced in NAb positive patients.  
Reflections 
Study II introduced me to gene expression analysis, how to use reference genes, 
and the delta-delta CT analysis method. In addition to this biological threshold 
value for NAb positivity was thoroughly explored.  
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during positive selection, and maintains naïve and memory T cell survival and homeostasis in 
the periphery (293-295). Generally, IL-7 is constitutively produced and its levels are 
unaffected by external signals (296). However, since IL-7 concentration in serum is elevated 
in lymphopenic humans (297), the expression can be modulated. A paper published by Lee 
and colleagues suggested that high endogenous serum IL-7 levels before IFNβ treatment 
onset, were a predictor of a good response (157). Consequently, we decided to investigate 
the relationship between IL-7 (genetically associated) and IFNβ (first-line treatment). A year 
later IL-7 levels could not be confirmed as a prediction of response status using a validation 
cohort (158), but using our already collected data we found that the serum samples from IFNβ 
treated MS patients had elevated IL-7 levels. 
4.1.2 Aim study I 
Determine if IL-7 homeostasis is affected by IFNβ and NAb. 
4.1.3 Elevated IL-7 levels as a consequence of IFNβ treatment 
For study I, our first finding was that IL-7 levels were elevated in MS serum after IFNβ 
administration. Whether the dosing schedule had an effect on the IL-7 levels was not initially 
a research question for us but was later found to be highly relevant for the project. We found 
that serum samples retrieved shortly after IFNβ administration had elevated IL-7 levels 
compared to samples collected more than 48 hours after the latest injection, suggesting that 
IFNβ somehow affected the IL-7 levels as measured by ELISA. Our conclusion was 
strengthened by the finding that the presence of high NAb titers (>1280 TRU/mL) to IFNβ 
resulted in significantly lower serum IL-7 levels compared to patients with NAb negative 
status. With the study II cohort we had the opportunity to validate our finding whether the 
serum IL-7 levels were affected by IFNβ in 20 MS patients using a paired t-test (not published 
data) (Fig. 33). The patients had left two serum samples at different time points. Our findings, 
illustrated in the graph below, show that the overall levels of IL-7 are significantly decreased 
Fig. 33. Serum IL-7 levels were 
significantly higher ≤14 hours, 
compared to ≥36 hours, since 
the latest IFNβ injection. 
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in patient’s serum 36 hours after the IFNβ injection compared to samples retrieved less than 
14 hours after the IFNβ injection. Except for two individuals the IL-7 levels went down 
between the two time points. 
Continuing using the study II cohort we could further validate our results showing that the 
NAb negative patients had elevated IL-7 levels compared to NAb positive patients (NAb titers 
above 200 TRU/mL) in serum samples retrieved ≥36 hours after the latest IFNβ injection (Fig. 
34).  
In study I, we also had IL-7 data (as measured by ELISA) for some of the patients after they 
had switched treatment to natalizumab. We concluded that it was the switching of treatment 
that resulted in decreased IL-7 levels, suggesting it was not the disease itself but rather the 
treatment that caused the change in concentration. Consistent with our result, Villani and 
colleagues recently published a paper showing that natalizumab treatment led to significantly 
reduced serum IL-7 levels in RRMS patients (298).  
Based on these observations we speculated that the elevation of serum IL-7 in IFNβ treated 
MS patients could be due to 1) increased production of IL-7 by stromal cells and/or 2) reduced 
expression of IL-7Rα on the cell surface. Since IL-7 is known to be constitutively secreted by 
stromal cells we hypothesized that the elevated IL-7 levels were caused by down-regulation 
of IL-7Rα rather than that the stromal cells started to produce IL-7 in excess.  
4.1.4 Reduced IL-7 consumption of cells exposed to IFNβ 
To explore what caused the changes in IL-7 levels, an in vitro model was used to study whether 
the PBMCs were affected by co-culture with IL-7 and IFNβ or IL-7 alone. Measured by ELISA, 
cells cultured with IL-7 and IFNβ resulted in lower uptake of IL-7 compared to the culture with 
IL-7 alone; suggesting that the receptor expression was altered on the PBMC when co-
cultured with IFNβ.  
Fig. 34. NAb positive patients had significantly lower 
serum IL-7 levels than NAb negative patients.  
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Using the IL-7 and IFNβ or IL-7 alone as culture 
settings we could see, by flow cytometry, a 
dose-dependent decrease in the IL-7Rα 
expression amongst CD14+ gated monocytes in 
response to IFNβ compared to cells cultured 
with IL-7 alone (Fig. 35). 
We further showed that MS patients initiated 
on IFNβ treatment, when followed for up to 13 
weeks, had an increase in plasma IL-7 levels, 
which inversely correlated with a down 
regulated IL-7Rα expression on their CD4+ T 
cells. These data collectively support our 
hypothesis that IFNβ treatment does in fact 
affect the expression of IL-7Rα.  
Our findings were further supported by samples from study II, which showed a similar pattern. 
We could, for example, see that IL-7Rα expression (amplification of total cDNA) was affected 
by NAb and that the NAb negative patients had significantly lower IL-7Rα than the ones with 
NAb and in particular with titers over 200 TRU/mL (Fig. 36).  
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Fig. 35. IL-7Rα expression was down-
regulated on CD14+ monocytes in a dose 
dependent manner. 
Fig. 36. IL-7Rα expression (total cDNA) was down-
regulated in the presence of high NAb titers to IFNβ. 
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 MxA has an inverse correlation to NAb and the graph below which includes study II samples 
show that high IL-7Rα gene expression levels yield low MX1 gene expression (r = -0.6029, p = 
<0.0001) (Fig. 37). 
 
 
 
 
 
 
 
 
Furthermore, we could also see that low IL-7Rα expression significantly correlated with high 
serum IL-7 levels (r = -0.3735, p = 0.0209) (Fig. 38).  
 
 
 
 
 
 
 
 
4.1.5 Conclusions for study I 
We found a 3-fold increase of serum IL-7 levels in IFNβ treated MS patients compared to 
natalizumab treated MS patients and healthy controls. Increased IL-7 levels were related to 
decreased IL-7 consumption, as shown by the lowered IL-7Rα expression on cell surfaces. 
Furthermore, the study provides a biological readout of the impact of NAb on IFNβ treatment 
and these results highlight the potential importance of a cytokine (IL-7), a receptor (IL-7Rα) 
genetically associated with MS, and the widely used RRMS treatment (IFNβ). The clinical 
effect of the elevated IL-7 levels should be further studied since it could potentially provide a 
Fig. 37. MX1 and IL-7Rα expression inversely correlated. 
Fig. 38. IL-7 levels and IL-7Rα expression inversely 
correlated. 
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pro-inflammatory stimulus. An interesting follow-up question to address is whether it is the 
decreased lymphocyte count, the reduced IL-7Rα expression, or the combined role that drives 
up IL-7 levels.  
4.1.6 Background study II 
Due to the occurrence of NAb to IFNβ it is important to establish reliable methods for NAb 
detection and to establish at what titer the biological activity of IFNβ is impaired. At the time 
of study II initiation MGA (278) was used in our laboratory to measure NAb to IFNβ, but were 
cumbersome and thus we wanted to find another assay that required less maintenance while 
maintaining reliable results. Therefore we compared MGA and iLite back to back to measure 
anti-IFNβ-antibody titers in order to evaluate the correlation of titers between these assays 
and further to estimate a biologically functional cut-point. A study published from our group 
had previously addressed the biologically functional cut-point and estimated it to be 150 
TRU/mL (198).  
4.1.7 Aim study II 
Compare two bioassays, iLite and MGA, to measure IFNβ specific NAb and to evaluate the 
NAb titer threshold that abrogates the biological activity of IFNβ. 
4.1.8 MGA and iLite gave similar NAb titers 
NAb titers measured with the MGA and iLite correlated (Fig. 39). There were some differences 
between the number of patients classified as NAb positive between the two assays. In the 
MGA, 64% (28 patients of 44) were recognized as NAb positive whereas iLite identified 48% 
(21 patients of 44) as NAb positive. Thus there was a discrepancy of 16% (7 patients), but 
these samples were, however, all classified with low NAb titers in the MGA assay. One thing 
we discussed during this project was that the serum concentration (MRD) might affect the 
readout and sensitivity of the assay (289). The MGA dilute the serum 1 to 10 (10%), whereas 
iLite diluted 1 to 20 (5%) and iLite thereby has a lower serum concentration in the assay. When 
validating the iLite method in study III we discovered that adding serum to the assay media 
increased the cells sensitivity to respond to IFNβ (299). I therefore assume that if we would 
Fig. 39. Comparison of IFNβ NAb 
titers using iLite and MGA. 
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reanalyze these 44 serum samples with the validated iLite IFNβ assay (study III) the seven 
samples that tested NAb negative might have turned out low positive.  
4.1.9 NAb titers above 150 TRU/mL block the effect of IFNβ 
To estimate a biologically functional cut-point we estimated the gene expression of two IFN-
induced genes, MX1 and CXCL10, following IFNβ injection and correlated with the NAb titer. 
We found that IFNβ administration caused upregulation of MX1 and CXCL10 (Fig. 40). IFNβ 
upregulated the expression of the two studied genes in NAb negative subjects and NAb 
positive individuals had a titer-dependent blockage of the IFNβ effect.  
This effect was also seen at protein level where NAb positive patients had significantly lower 
levels of protein CXCL10 in the blood compared with NAb negative patients, as measured by 
ELISA (Fig. 41). 
  
 
Fig. 40. Correlation of the relative gene expression of 
CXCL10 and MX1 with NAb titers (measured by iLite). 
Fig. 41. Protein CXCL10 levels 
were down-regulated in the 
presence of high NAb titers 
to IFNβ. 
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4.1.10 Conclusions for study II 
The traditional cell based inhibition assay (MGA) and the luciferase reporter gene assay (iLite) 
were directly comparable when measuring IFNβ-specific NAb titers and could therefore 
replace MGA in our routine setting. We further showed that both assays identified a medium 
titer of 150 TRU/mL as a biologically threshold for significant neutralization as previously 
shown (198). Our results also show that lower NAb titers may impact the effect of IFNβ, 
although to a lesser extent. We therefore believe that it would be of biologically relevance to 
set a new evidence-based threshold for both assays. We also believe that the NAb levels 
should be monitored regularly during treatment with IFNβ as NAb clearly affect IFNβ 
bioavailability. The activity of IFNβ is already affected at titers between 10 and 150 TRU/mL 
and treatment should be monitored, and discontinued, if treatment effect decreases. In the 
case of confirmed NAb titers above 150 TRU/ml switching drugs should be considered even 
before breakthrough of disease is evident.  
 
 
 
 
 
  
KEY POINTS 
 IFNβ treatment leads to elevated serum IL-7 levels. 
 Cells exposed to IFNβ in vitro have reduced IL-7 consumption. 
 MGA and iLite were directely comparable to measure IFNβ-specific 
NAb titers. 
 NAb titers above 150 TRU/mL block the effect of IFNβ in vivo. 
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4.2 STUDY III 
 
4.2.1 Background 
The majority of routinely used cell-based IFNβ NAb assays utilize the Kawade principle to 
calculate NAb titers (including MGA and iLite). The Kawade method has statistical limitations 
as it assumes that NAb only are relevant if they can neutralize IFNβ by at least 90%. The cut-
point approach is designed to be more sensitive than the Kawade method since it relays on a 
more robust statistical evaluation using a group of individuals (around 50 is recommended) 
to identify a cut-point where a signal above is recognized as NAb positive.  
This work was part of the "Anti-Biopharmaceutical Immunization: prediction and analysis of 
clinical relevance to minimize the RISK" (ABIRISK) consortium. All work with the iLite assay 
was performed at Karolinska Institutet, Stockholm and the LUC assay was validated at two 
sites including Innsbruck Medical University and Rigshospitalet Copenhagen. Since my 
responsibility was to address re-development and validation of iLite, the data presented here 
describes mainly the work with iLite. 
4.2.2 Aim 
The aim of this study was to re-develop and validate the LUC and iLite cell-based assays using 
a cut-point design, instead of the Kawade principle, to identify NAb positive samples to IFNβ.  
4.2.3 Pre-validation 
The pre-validation was performed using three steps. In short, as a first step IFNβ dose 
response curves were run to determine the EC50 (50% of IFNβ maximum effect on the cells). 
As a second step, the selected stimulation concentration of IFNβ (EC50) was used to perform 
Development and validation of cell-based luciferase reporter gene assays for 
measuring neutralizing anti-drug antibodies against interferon beta. 
Hypothesis  
A validated bioassay, according to industry recommendations, will provide a 
sensitive and reproducible assay for quantification of NAb to IFNβ. 
Reflections 
Initiated at the outset of my Ph.D. research, this study afforded me greater 
experience of how to ensure quality assay design – a skill highly relevant for my 
other studies during my Ph.D. Moreover, this project gave me the opportunity 
to learn advanced statistical concepts, calculations, and SOP documentation. 
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anti-IFNβ antibody inhibition curves with the aim to select a low- and a high IFNβ positive 
control. In a final step, the selected EC50, HPC and LPC were tested, using the Z-factor score, 
to ensure quality of the assay. 
4.2.3.1 Serum increased the assay sensitivity 
During our extensive pre-validation work, we noticed that the addition of human serum (1 in 
20 to 1 in 50) to the assay media increased the sensitivity and recovery of the assay (Fig. 42). 
After running several anti-IFNβ antibody dose response curves, we chose to include 2.5% (1 
in 40) human serum to the assay media, demonstrating the importance of addressing the 
matrix effect.  
 
4.2.3.2 The EC50 
The first step in the pre-validation work was to establish an EC50 i.e. the IFNβ concentration 
required to stimulate the cells by 50% of their maximum. For iLite, this was calculated to be 
1.3 international unit/mL (Fig. 43). No significant variations were found between the EC50 
values using the different serum dilutions (1 in 20 to 1 in 50) used for the dose-response curve 
experiment.  
 
 
 
 
 
Fig. 43. Calculation of the EC50 using dose-response 
curves. 
Fig. 42. Added serum to the assay media made the cells 
more receptive to IFNβ stimulation. 
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4.2.3.3 High and low positive controls 
We then used the selected EC50 concentration of IFNβ to perform anti-IFNβ inhibition curves 
to define the high and low positive control. The HPC and LPC were defined using 11 
concentrations of the anti-IFNβ antibody that was diluted 2-fold from 800 ng/mL to 0.78 
ng/mL in assay media containing human pooled serum at concentrations 1 in 30, 1 in 40, 1 in 
50, 1 in 60 and assay media only (Fig. 44). The concentrations of anti-IFNβ antibody that 
inhibited the maximum EC50 signal by 25% (LPC) and 60% (HPC) was calculated to correspond 
to 480 ng/mL and 800 ng/mL respectively in neat serum.  
 
 
 
 
 
 
 
 
 
4.2.3.4 Z-factor 
The quality of the assay was assessed by calculating the Z-factor score. We found that the HPC 
and LPC had a Z factor of 0.76 and 0.65 (separation score from the negative signal) 
respectively when using assay matrix 1 in 40. Since a score between 0.5 and 1 is considered 
to reflect an excellent separation of the positive and negative signal, the pre-validation 
criteria´s for iLite were therefore accepted and allowed us to start the validation work (Table 
IV) using 1 to 40 as dilution factor. 
 
 
 
Table IV.  
Fig. 44. Selection of a high and low positive IFNβ control. 
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4.2.4 Validation 
4.2.4.1 A floating cut-point was applied  
The assay cut-point is the response level that defines if a sample response is positive or 
negative. The cut-point was retrieved as summarized in the flowchart below.  
 
In short, the healthy control serum samples were more normally distributed and symmetrical 
using the linear scale (W = 0.92, skewness = 0.39) compared to log-transformed data (W = 
0.91, skewness = 0.32) as indicated by that the W factor and skewness factor were bigger for 
the linear distribution (Fig. 45). 
 
 
 
 
 
 
 
 
 
Fig. 45. Evaluation of the sample distribution using the linear scale versus the 
logarithmic scale. 
 57 
 
Therefore, we did not need to transform the data for continued work. The box plot method 
was used to illustrate the differences and spread of the samples and no biological outliers 
were identified. However, two analytical outliers were identified and these were removed 
from the individual runs. Biological outliers refer to the removal of samples that stands out 
from a response rate from the whole population tested. Analytical outliers refer to samples 
that are outliers, compared to the other samples, in one individual run. For the majority of 
runs, Shapiro-Wilk test indicated normal distribution since the p-value was higher than 0.05, 
and a skewness coefficient below 1. The healthy control samples used to establish the cut-
point was confirmed to be directly proportional to the response of the negative control, which 
could be used for normalizing of the cut-point (Fig. 46). 
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The parametric approach was used to calculate the cut-point (284). The majority of 
immunogenicity assays use a floating cut-point, which has the advantage of not being 
sensitive to variation in signal between plates. In our assay, a floating cut-point was used since 
the variance around the mean was constant but mean response of negative control varied 
between plates and analysts.  
4.2.4.2 Limit of detection 
Next, we assessed assay sensitivity by running antibody dilution curves. The anti-IFNβ 
antibody was titrated spanning the cut-point. The sensitivity of the assay gives an indication 
of the lowest concentration analyte (NAb antibodies) that can be statistically distinguished 
from the background signal, and at the same time adequately precise to be quantified. The 
iLite assay was shown to have a very high sensitivity with a limit of detection (LOD) of 320 
ng/mL.  
Fig. 46. The response values of the negative control was 
directly proportional to the healthy control samples. 
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4.2.4.3 iLite lot variation stopped further validation work 
In the end of the validation work, we had to switch iLite batch due to that the iLite kits we 
started the validation process with were used up. To our surprise, the cells from the three 
new batches responded differently to IFNβ stimulation. As illustrated in the graph below the 
new cell lot´s responded significantly less than the originally used lot that the cut-point was 
based upon (Fig. 47).  
 
 
The batch differences turned out to be a major problem for us since it affected our cut-point 
based method and resulted in that the established EC50 could not be applied to the new cell 
batches, and that the cut-point needed to be re-established.  
4.2.5 The importance of a validated bioassay 
I believe that all ADA bioassays must be validated by using the same internationally agreed 
standard to ensure quality and reliability of the data generated. If we compare ADA frequency 
between different laboratories there is a huge discrepancy in the percentage being positive. 
The differences can, of course, be based on many factors but I believe that the assay 
sensitivity is one major issue. Validation will provide proof that what the assays detect is 
actually what you want it to detect and that it does not suffer from artifacts. The long-term 
goal was to design an assay that was sensitive enough to find all patient samples that were 
reactive (NAb) towards the drug (IFNβ). Thereafter we would investigate the specificity of the 
reactivity to establish a clinically relevant threshold for when the NAb would affect the drug 
in a way that it becomes relevant for the patient, i.e. when the patient loses the effect of their 
treatment. 
Fig. 47. Cell batch variations were identified between lots. 
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4.2.6 Conclusions 
This work provides a detailed description of re-development and validation of two luciferase 
reporter gene bioassays, LUC and iLite, using a cut-point approach to identify NAb positive 
samples in IFNβ treated MS patients. The validation was conducted according to the latest 
assay guidelines preferred by the pharmaceutical industry and governmental regulatory 
agencies. Due to the batch differences using the iLite assay, this assay could not be used for 
NAb testing. Instead, the LUC (Copenhagen) assay was chosen.  
The use of the cut-point increased the assays sensitivity for NAb detection. Using the validated 
LUC (Copenhagen) cut-point assay, 12% more NAb positive samples were identified when 
compared with the Kawade method. We could further show that discrepant samples (NAb 
negative with Kawade and NAb positive with cut-point) had an average relative gene 
expression level that was two-fold (MX1) and four-fold (CXCL10) lower than the samples that 
were NAb negative with both assay designs (Fig. 48). This reduction indicates a possible 
biological effect even for low NAb titers that could be of clinical importance, although the 
relevance needs to be further evaluated.  
 
 
 
Fig. 48. NAb discrepant samples had an average relative gene 
expression that was two-fold (MX1) and four-fold (CXCL10) lower 
than the samples that were NAb negative. 
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KEY POINTS 
 Validation was performed following the latest assay guidelines 
accounting for matrix effects and using cut-point design. 
 iLite showed high sensitivity and specificity. 
 The validation work resulted in increased sensitivity to detect 
NAb. 
 
1.  
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4.3 STUDY IV 
 
4.3.1 Background 
For RA patients on TNF-α inhibitor treatment, serum drug trough levels are not routinely 
monitored in the clinics. As of today, there is no consensus on how often IFX levels should be 
measured or the optimal drug trough level. For the optimal patient benefit, individualize 
therapeutic regimens should be implemented. A study by Casteele and colleagues showed 
that an IFX serum trough concentration between 3 to 7 µg/mL was optimal dosing for patients 
with inflammatory bowel disease (300). Another study showed that IFX treated patients with 
inflammatory bowel disease with a serum trough level below 6.2 µg/mL were more likely to 
experience loss of response (301). Since no published guidelines are available for the optimal 
trough IFX concentration in RA patients, we chose to implement the recommendation 
suggested by Casteele for our study. A drug level below 3 µg/mL was regarded as too low, a 
level above 7 µg/mL as too high, and a level of 3-7 µg/mL as optimal. These recommendations 
must, however, be correlated to the patient´s clinical parameters to assess whether this 
interval is the correct dosing regimens for our cohorts. This will be performed when we 
receive data from the Swedish Rheumatology Quality register (SRQ).  
4.3.2 Aim 
The aim and long-term goal of this study was to combine pharmacokinetic and 
immunogenicity results with the patients’ clinical response to propose an algorithm for 
monitoring and interpreting the treatment response to IFX. Moreover, we investigated what 
type of assay that should be used for monitoring of the IFX immunogenicity.  
Measurement of serum infliximab levels and detection of free and bound anti-
infliximab antibodies in patients with rheumatoid arthritis  
Hypothesis  
Monitoring of serum IFX levels and ADA in RA patients will enable 
identification of patients with optimal treatment response, give an indication 
to why some patients not benefit from this type of treatment and what 
treatment alternatives that instead should be considered. 
Reflections 
Because my previous work has primarily been focused on IFNβ (cytokine) and 
MS, this project afforded me new insight into the complexity of autoimmune 
diseases and mAb therapy.  
 
 
 
 62 
 
4.3.3 Few patients have an optimal TNF-α inhibitor drug level  
One part of the project was to study the serum TNF-α inhibitor drug levels in people with RA. 
Overall, in both the SWEFOT and REALlife cohorts we observed that only a quarter of the 
patients had an optimal drug concentration (Fig. 49). In the SWEFOT cohort, only 24% of the 
patients had a drug concentration within the optimal range of 3-7 µg/mL after 21 months on 
TNF-α inhibitor treatment. Too low drug levels (<3 µg/mL) were found in 46%, and too high 
drug levels (>7 µg/mL) were found in 31%. In the REALlife Stockholm cohort (either new to 
treatment or >2 years on treatment), 70% had an IFX level below 3 µg/mL and only 6% above 
7 µg/mL. Only 24% had a drug level of 3-7 µg/mL. Despite differences in the number of 
individuals with either too low or too high drug levels, the two cohorts exhibited the same 
fraction of patients with optimal dosing interval (24%). Thus, the majority of patients appear 
not to have the ideal drug concentration and our data, therefore, reinforce the importance of 
“drug level test adjusted treatment strategies” at the clinic to allow for an optimal dosing 
plan. 
 
 
4.3.4 PandA could detect ADA in samples with detectable drug levels 
4.3.4.1 The pattern for ADA positivity differed between the ELISA and PandA 
ADA could be detected in the majority of serum samples with a drug level below 0.2 µg/mL, 
as measured by ELISA. What was unexpected in the SWEFOT cohort was that the ADA results, 
if categorized for the individual patient over time, could be classified into seven groups based 
on the different patterns for ADA positivity (Table I, manuscript nr. IV). It should be noted that 
patient serum samples with a drug level above 0.2 µg/mL are not screened for ADA since the 
ELISA is drug sensitive. Therefore, a sample with a drug level above 0.2 µg/mL is automatically 
regarded as ADA negative without actually being screened for ADA. However, we had the 
advantage of having the PandA method (acid dissociation) that allowed samples to be 
screened for ADA regardless of the drug concentration. Thus, we analyzed some of the 
Fig. 49. TNF-α inhibitor drug levels in two RA cohorts. 
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patient’s three consecutive samples at 3, 9 and 21 months post-treatment initiation that had 
not previously been screened for ADA. When the patients were classified according to the 
ADA results retrieved with the PandA, the pattern for ADA positivity changed (Table II, 
manuscript nr. IV), and we found that ADA could be detected earlier with the PandA assay 
than with the ELISA. Moreover, the number of patients regarded as ADA transient reduced 
from fifteen (as measured by ELISA) to two with the PandA method. Though the clinical 
importance of these findings need to be further evaluated, it gives us the opportunity to 
analyze some of the samples with unexpected results in the ELISA. As an example, one patient 
sample tested ADA positive after 3 months post-treatment initiation (drug level below 0.2 
µg/mL) using the ELISA. At 9 months post-treatment initiation, the same patient left a sample 
with a drug level of 1.8 µg/mL and were thus categorized as ADA negative or rather 
undetermined as ADA could not be measured by ELISA. At 21 months post-treatment 
initiation, the patient tested ADA positive again (drug level below 0.2 µg/mL). The sample at 
9 months post-treatment initiation was therefore tested with PandA and tested ADA positive 
(with a high titer). This is an example when the PandA method is useful as a complement to 
the ELISA method. 
4.3.4.2 Undetectable drug levels and ADA negative 
All patients in the REALlife cohort with a drug level below 0.2 µg/mL tested ADA positive with 
ELISA, whereas in the SWEFOT study 14% with a drug level below 0.2 µg/mL did not have 
detectable ADA with ELISA. We speculated that the samples had drug/ADA immune complex 
formations that could be separated using the PandA assay. However, only one sample showed 
moderate ADA reactivity when measured with PandA. In the REALlife cohort (which includes 
more patients than SWEFOT), we could not find any samples showing the same pattern of 
having low drug levels and at the same time be ADA negative. One difference between the 
two cohorts is that all patients in the REALlife study are treated with IFX, which is 
administrated intravenously at the clinic. In the SWEFOT cohort, the patients could have 
switched treatment to adalimumab or etanercept, both drugs are administrated s.c. at home. 
Although we have no evidence of this, one should be aware of the possibility that the 
undetectable drug levels could be due to poor treatment compliance.  
4.3.4.3 Up to what drug trough level should ADA be monitored? 
As ADA is only measured in serum samples with a drug concentration below 0.2 µg/mL we 
wanted to investigate if we could detect ADA in serum samples with a drug concentration 
between 0.2 µg/mL to 7 µg/mL. Interestingly, ADA reactivity could indeed be detected in 
many of these samples using the PandA method (Fig. 50). In the SWEFOT cohort, we found 
more ADA reactive samples than in the REALlife cohort (Stockholm). My interpretation of the 
difference seen between cohorts is that the SWEFOT cohort included patients from treatment 
initiation for up to 21 months, whereas the REALlife cohort were either new to treatment or 
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had been treated for more than two years. Therefore, the samples in the SWEFOT cohort 
were retrieved in a timeframe when most patients would develop ADA and identification of 
ADA reactive samples are thus expected. In contrast, the REALlife study included patients who 
had been treated long term and therefore likely to respond well compared to the ADA positive 
patients who may already have switched to other treatments. Furthermore, the newly 
treated patients included in this cohort may not yet have developed ADA. In the graph below 
(Fig. 50), the dotted line on the y-axis represents the cut-point for ADA reactivity using the 
PandA method. As previously mentioned the significance of these findings needs to be further 
addressed and coupled to clinical data (SRQ registry). As of now we speculate that a 
recommendation for ADA screening should be implemented for serum samples with a drug 
level below 3 µg/mL. 
  
 
 
 
 
 
 
 
 
4.3.5 Neutralizing ADA (iLite) correlates to a certain extent with % inhibition (ELISA)  
Serum samples from the REALlife (Stockholm) cohort that tested ADA positive with the ELISA 
were further tested for neutralizing ADA using the iLite bioassay. iLite characterized 66% of 
the patients (19 of 29 patients) or 71% of the samples (25 out of 35 samples tested from the 
29 patients) as positive for neutralizing ADA. We then decided to correlate the RLU signal 
generated in iLite with the % inhibition (to the blank) in the ELISA measurement to investigate 
if the % inhibition was predictive of the ADA neutralizing capacity (Fig. 51). The dotted line on 
the y-axis represent the cut-point for when the sample is regarded as NAb positive (iLite). The 
dotted line on the x-axis represents the % inhibition in the ELISA where we suggest could be 
a hallmark for when a serum sample should be regarded as neutralizing. Overall the 
correlation of the assays were good. The samples that tested NAb negative in the iLite assay 
clustered together with the samples that had a low % inhibition in the ELISA, with the 
exception of two samples (samples are marked in blue and green). The samples that had 
≈100% inhibition (ELISA) clustered with the highest RLU values (iLite), with the exception of 
Fig. 50. PandA identified ADA reactivity in serum samples 
with detectable drug levels. 
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one sample (marked in green). However, as many as ten samples tested NAb negative with 
the iLite assay that tested ADA positive with the ELISA. Since the iLite assay have the potential 
of drug/ADA interference, we wanted to run these samples on PandA. 
 
 
The PandA assay identified 92% (36 out of 39 samples) as ADA reactive (not confirmed ADA 
positive) (Fig. 52). The dotted line on the y-axis represent the cut-point for when the sample 
is regarded as ADA positive (PandA). The dotted line on the x-axis represents the cut-off for 
the % inhibition that suggest neutralizing ADA as measured by the ELISA. Out of the ten 
samples that tested NAb negative in the iLite, only three samples tested ADA negative with 
the PandA but the seven samples that tested positive had a very low ADA reactivity (<1.5 
Relative ECL ) and would most likely turn ADA negative when titrated in the confirmatory step.  
 
  
Fig. 51. Correlation between the % inhibition (ELISA) versus 
NAb (iLite). 
Fig. 52. Correlation between the % inhibition (ELISA) versus 
ADA (PandA). 
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The results from the iLite and PandA have thus a good correlation (Fig. 53). The dotted line 
on the y-axis represent the cut-point for when the sample is regarded as ADA positive 
(PandA). The dotted line on the x-axis represents the cut-point for when the sample is 
regarded as NAb positive (iLite).  
 
 
In summary, out of the 40 samples that tested positive in the ELISA, 93% (36 out of 39) tested 
positive for ADA reactivity in the PandA, and 71% (25 out of 35) tested NAb positive in the 
iLite assay (Table V).  
 
 
A study by Schie and colleagues showed that the majority of ADA to IFX (>90%) were 
neutralizing (87), but we identified fewer patients with neutralizing ADA (66%). Our data was 
strengthened by that samples that tested NAb negative with the iLite assay also tested ADA 
negative or had very low ADA reactivity in the PandA assay. Thus, the ELISA is more sensitive, 
but might lack in specificity. 
 
Collectively, our data suggest that serum samples with an inhibition below 70% should not 
immediately be regarded as neutralizing without further confirmatory NAb/ADA testing. 
Since the PandA and iLite assays correlate well, any of these two assay could be an option to 
confirm ADA/NAb positivity. If no NAb or high titer ADA can be detected with the iLite or 
PandA, dose escalation and/or increased dosing intervals might be beneficial.  
Fig. 53. Correlation between iLite and PandA to measure 
NAb and ADA respectively. 
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4.3.6 Proposed treatment algorithm 
Based on the results of the IFX concentration and ADA measurements retrieved so far we 
suggest the following preliminary algorithm for monitoring of IFX. These recommendations 
will, however, be adjusted when the clinical data are analyzed from the SRQ registry. 
Treatment decisions should be adjusted depending on the patient’s disease state. 
As a pilot algorithm, we suggest that the patient’s drug level is monitored with ELISA every 3 
months during their first treatment year (Fig. 54). Patients with either a very low (<0.2 µg/mL) 
or low (0.2-3 µg/mL) drug level should be analyzed for ADA with ELISA or PandA. If the patient 
is ADA positive, it would suggest that the patient should change treatment plan if they have 
an active disease. Patients in remission could stop their current treatment and await a new 
treatment plan. If the patient is ADA negative they should change treatment if active disease, 
since this indicates that they probably need a drug with another mode of action. Patients in 
remission should continue treatment since they most likely have benefit of their treatment. 
If the patient has high drug levels (>7 µg/mL), dose tapering might be beneficial. By combining 
monitoring of drug levels and ADA with clinical data, the clinician will be able to optimize the 
treatment of individual patients in a more efficient way and thus both reduce patient disease 
management and healthcare costs. As of today, the red numbers are still unknown. 
  Fig. 54. Pilot algorithm to monitor IFX treatment.  
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4.3.7 Conclusions 
A substantial proportion of RA patients are considered non-responders to their TNF-α 
inhibitor treatment. Not only is it a problem for the patients that are on a treatment plan that 
is ineffective and therefore not actually giving the intended treatment benefits, but it is also 
a problem from a health-economical perspective. In Sweden alone, if we estimate that around 
30% of the treated patients with the top 10 most sold drugs in Sweden are ADA positive, then 
≈815 million Swedish kronor are spent on drugs that are ineffective yearly.  
We as researchers have the responsibility to translate our findings to clinicians in an effective 
way in order to facilitate implementation of translational research. Rogers model of diffusion 
of innovation describes how new knowledge can be distributed efficiently and are categorized 
into four groups: (1) innovation (2) communicated through certain channels (3) over time (4) 
among the members of a social system (302). With the data generated summarized in the 
treatment algorithm, we hope to channel out our experience and contribute to easier 
treatment decision making. 
 
 
 
 
 
 
  
KEY POINTS 
 Only 24% of the patients had optimal drug levels after 21 
months of treatment. 
 Serum samples with a drug level above 0.2 µg/mL were 
screened for ADA with PandA and up to 51% tested positive for 
ADA reactivity. 
 Neutralizing ADA was found in 66% of the patients tested. 
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4.4 STUDY V 
4.4.1 Background 
IFNβ is a widely used therapy for RRMS and administration of IFNβ can result in the 
development of NAb in as many as 47% and negatively affects the treatment response. S.c. 
administration is suggested to be more immunogenic than the i.m. route (206). The 
mechanisms of induction of immunological responses against biological drugs administered 
through the skin are still relatively unknown. Buttmann and colleagues investigated the 
impact of s.c. IFNβ administration on cell infiltration to the site of injection (167). They found 
chemokines expression and T cell and macrophage infiltrates at the injection site suggestive 
to cause inflammatory skin reactions.  
The skin is an important immunological barrier (303) and to the best of our knowledge, this is 
the first study investigating the local biological role of IFNβ using a human ex vivo skin model. 
The model had previously only been used in vaccination studies (304, 305). Additionally, we 
have studied the impact of IFNβ by sampling skin biopsies after IFNβ injections in MS patients.  
4.4.2 Aim 
The aim of this study is to monitor the migration status of skin cells and surrounding matrix 
after administration of three different IFNβ preparations. This was studied in an ex vivo skin 
model as well as in vivo to determine if the different immunogenicities of the IFNβ 
preparations were evident at the injection site. 
Different interferon beta preparations induce the same qualitative immune 
response in human skin 
Hypothesis  
Repetitive IFNβ injections activate skin dendritic cells and promote the 
dynamic recruitment of other cells to the injection site that over time 
correlate with risk of ADA development. 
Reflections 
I found this study particularly challenging due to the laboratory skills required 
while it led to personal development as a researcher. In this project I worked 
independently with the laboratory experiments and solved problems as they 
came along. This led, among other things, to me spending two months in 
Amsterdam to learn the skin model method. 
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4.4.3 Intradermal IFNβ injection led to decreased cell migration but increased the 
percentage of CD86 expression. 
Initially, we thought that IFNβ treatment would promote cell migration from the tissue. 
Unexpectedly it was the opposite. The higher concentration of IFNβ led to lower cell migration 
than the low dose IFNβ and the PBS control. I believe this could partly be due to the saturation 
of IFNβ and that cells potentially may have been killed. This is supported by that increased 
staining of high mobility group box (HMGB) 1 during immunohistochemistry indicating cell 
death (306). However, I did not use a cell death marker during the immunohistochemistry 
procedure to confirm this. If the high dose IFNβ led to cell death, it could explain the event of 
fewer DC in the tissue media (cell counting) and lowered frequency detected during flow 
cytometry analysis compared to the low dose IFNβ and PBS. Interestingly, the high dose IFNβ 
induced a higher percentage of CD86 positive CD1a+ and CD14+ DC suggesting that IFNβ 
induced cell activation of the skin cells that migrated from the skin site. So despite the fewer 
cells migrating, the ones that did had an expression of CD86, which suggests enhanced 
activation. 
4.4.4 Decreased CD4+ T cell proliferation  
Increased naïve CD4+ T cell proliferation was not observed after co-culture with IFNβ treated 
DC. Intradermal administration of IFNβ hampered the ability of the crawl-out DC to promote 
proliferation of allogenic naïve CD4+ T cells compared to PBS treated DC when using 
luminescence detection of intracellular ATP as a measure of cell numbers. These data seem 
to conflict with our results showing enhanced expression of costimulatory molecules HLA-DR 
and CD86, which indicates a mature phenotype. However, several studies have shown that 
IFNβ alters the function of antigen presenting cells by downregulating their antigen 
presentation ability and thus their ability to stimulated T cell responses. 
4.4.5 IFNβ injection led to proinflammatory cytokine production 
Microscopic examination was performed to evaluate the impact of IFNβ injection after 
immunohistochemical staining with different inflammatory markers. The biopsies were 
collected 90 minutes and 24 hours after sampling. After 90 minutes, we could see increased 
staining of the epidermis and dermis of HMGB1, IL-1β, IL-6, and Cyclooxygenase-2 (COX-2) in 
IFNβ-injected skin compared to the saline control and the uninjected biopsies sampled. 
Prostaglandin E2 (PGE2) and toll-like receptor (TLR) 4 had similar staining intensity in IFNβ-
injected skin and the saline control site. After 24 hours, the saline injected biopsies showed 
overall similar staining intensity as the IFNβ-injected skin sites, and the uninjected sites 
showed weak to negative staining. MxA was used as a positive control for IFNβ and was 
increased first after 24 hours after the IFNβ injection compared to the saline and uninjected 
biopsies. We believe that when the cells are subjected to stress, such as the event of IFNβ 
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injection or at some instances the injection with PBS, this will contribute to cell death and the 
release of HMGB1 (307, 308) as illustrated in the simplified picture below (Fig. 55). 
 
 
 
 
 
 
 
 
HMGB1 is localized in the cell nucleus in all nucleated cells. Upon danger signals, as a result 
of cellular stress and cell damage, HMGB1 is released to activate an immune response (309). 
When released, HMGB1 induce secretion of proinflammatory cytokines by inducing nuclear 
factor kappa B signaling downstream of TLR2 and TLR4 (310). Thus, the induced secretion of 
proinflammatory cytokines including IL-1β and IL-6 (311) could be due to HMGB1 release 
contributing to local inflammation in the tissue. 
4.4.6 Different IFNβ preparations - same immune response? 
Evidence suggests that the three different IFNβ preparations elicits different immunogenicity. 
While IFNβ-1b gives low titer NAb often of IgM subtype, IFNβ-1a (i.m.) and (s.c) give rise to 
persistent high titer NAb often of IgG subtype. In our ex vivo assay, we found that when the 
IFNβ preparations were normalized in regards to units and site of injection (intradermal) there 
were no significant changes in the way the dendritic skin cells responded. Depending on the 
IFNβ preparation used for treatment there is a substantial difference in how many units of 
IFNβ patient receive over one year. IFNβ-1b and IFNβ-1a (s.c.) are known to be most 
immunogenic and over a year they are received at 1460 million units and 1872 million units 
respectively in contrast to IFNβ-1a (i.m.) that is considered to be of lower immunogenicity 
and is received with 312 million units during one year. 
4.4.7 Are the skin reactions important for the ADA formation? 
In the vaccine field, human skin explant models are used to investigate the impact on skin-
resident cells due to their immune responsiveness and high accessibility (312). These types of 
studies have not yet been implemented for biological drugs. Since biological drugs often are 
administrated either s.c. or i.m., thus through the skin route, I found it highly relevant to 
investigate the local immune effect. A majority of people treated with IFNβ are suffering from 
Fig. 55. Proinflammatory cytokine release initiated by HMGB1. 
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injection site reactions (313) and the cause and effect of these reactions have not been 
extensively studied. Our data suggests the release of inflammatory cytokines which, at least 
partly, could explain the reactions seen at the skin site after drug administration. To minimize 
the risk of immune activation at the injection site the use of a topical anti-inflammatory cream 
such as hydrocortisone could be applied before IFNβ administration (314).  
Since IFNβ is administrated with repetitive injections it is probable that the skin DC at the 
injection site are triggered to 
become activated (Fig. 56). A 
possible chain of events could be 
that after the IFNβ injection the 
skin resident DC engulf and 
process IFNβ to peptides, migrate 
to the lymph node where the 
peptides will be presented to T 
cell clones, that in turn become 
activated. The T cells will further 
activate B cells resulting in anti-
IFNβ antibody producing plasma 
cells.  
 
4.4.8 Conclusions 
In our ex vivo skin model, we found that injection with IFNβ significantly enhanced maturation 
of skin DC. We could further demonstrate that IFNβ injection elevated the expression of 
alarmin and several inflammatory cytokines at the skin site. These findings were further 
validated in the MS biopsies, where similar results were observed. We could also show that 
when three different IFNβ preparations were normalized, with regards to dose and injection 
site, the immune responses to the drug gave similar results. This indicates that the differences 
in immunogenicity between the different IFNβ preparations are more likely due to the route 
and frequency of administration, rather than the formula of the preparations. Our findings 
suggest that IFNβ administration triggers an immune response at the injection site through 
local cytokine release and cell maturation. We hypothesize that this may be the first in a series 
of events that lead to ADA formation. A better understanding of these molecular and cellular 
events could be explored to modify immunogenicity of drugs.  
 
     Fig. 56. Immunity of the skin. 
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KEY POINTS 
 Both intradermal and subcutaneous administered IFNβ 
initiated a pro-inflammatory cytokine release at the site of 
injection. 
 Skin-resident cells had increased expression of costimulatory 
molecules after IFNβ injection. 
 When three different IFNβ preparations were injected at the 
same skin site with the same dose there were no qualitative 
differences in the immune response. 
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5 REFLECTIONS AND THESIS SUMMARY 
5.1 BIOPHARMACEUTICALS AND THE IMMUNOGENICITY ISSUE - STRENGTHS, 
LIMITATIONS AND FUTURE DIRECTIONS 
5.1.1 Strengths 
The introduction of biological therapeutics has significantly improved the daily function and 
quality of life for a substantial number of individuals with chronic inflammatory diseases. 
Treatment efficacy can be clinically monitored by slowed disease progression and significant 
reductions of disease symptoms. The expanding knowledge of biopharmaceuticals aids in 
both the development of improved therapeutics as well as providing a broader panel of 
therapeutics available. Making alternative drugs available has the advantage of allowing the 
replacement of one drug with another to increase treatment efficacy.  
5.1.2 Limitations  
The overall aim of my thesis was to characterize one obvious limitation with 
biopharmaceuticals: the development of ADA/NAb. In study I – IV we have shown that the 
presence of ADA/NAb have a negative impact on the serum drug concentration. For example, 
in study IV, we showed that only a quarter of the patients had optimal drug levels after 21 
months of treatment and that ADA was detected in the majority of serum samples with a 
drug level below 0.2 μg/mL. In study I – III, the impact of NAb was also shown on the gene 
expression level where the biological response to IFNβ was abrogated in presence of high titer 
NAb. Thus, ADA is a major concern to achive a safe and efficient treatment course. The long-
term safety of biologicals developed to mimic human endogenously produced proteins are 
crucial to discuss already during drug design and development. For example, ADA to 
therapeutically administered IFNβ has been shown to also interfere with endogenous IFNβ 
(198). The long-term consequences of ADA development have not yet been scientifically 
shown but it is, of course, important to follow these patients to evaluate any negative impact 
on aspects such as for example combating virus infections. With continuous releases of new 
biological therapies it is now more than ever important to strive for less immunogenic drug 
compounds.  
Another limitation of drug therapy is injection site reactions after drug administration which 
can bring discomfort and pain to the treated patients. In study V, by immunohistochemistry, 
we identified several inflammatory cytokines at the injection site after IFNβ injection, both in 
vivo and ex vivo that potentially could trigger the swelling and irritation. Furthermore, since 
skin cells sometimes are targeted for vaccine delivery to induce a strong immune response it 
is tempting to visualize a link between the local inflammation triggered by IFNβ and the 
potential to induce ADA/NAb development.  
 75 
 
5.1.3 Future directions 
Future research should strive to overcome the limitations outlined above. This aim is 
achievable with the immunological knowledge and immunoassays that we have today, and 
can develop in the future, to measure immunogenicity with high specificity. This was 
addressed in study III were we showed that when validation was performed following the 
latest assay guidelines, increased sensitivity to detect NAb was achieved. When reliable NAb 
testing strategies are available the results could be merged with clinical data to allow the 
structuring of algorithms used as treatment outcome predictors. Higher accuracy would allow 
meaningful use in clinical practice as discussed in study IV.  
Effective and safe treatment could be achieved by collaboration and bridging the knowledge 
gap between researches, clinicians, and biopharmaceutical companies. Moreover, a 
structured monitoring of immunogenicity in clinical routine can stimulate and reward future 
development of improved therapeutics that are less immunogenic and have a prolonged 
serum half-life. Below are some good examples of how this could be accomplished. 
5.1.3.1 Prediction of T cell mediated immune responses 
To engineer less immunogenic therapeutics is scientifically challenging. Since ADA mostly are 
of IgG isotype, it is suggested to be a T cell-mediated response. Different screening methods 
can be used to localize regions within the drug protein sequence that contribute to 
immunogenicity, and measure T cell dependent immune responses to therapeutics to predict 
immunogenicity. Deletion of T cell epitopes or amino acid substitutions have the potential to 
reduce immunogenicity. Methods used for predicting T cell responses include cell epitope-
screening (in silico), where the regions of interest can further be validated in an HLA binding 
assays (in vitro) to measure affinity (315). However, as with all predictive models, they must 
be validated in a clinical testing to confirm improved properties of the de-immunized 
therapeutic. 
5.1.3.2 PEGylated therapeutics 
Since the early 1990s, there is a growing use of PEGylated therapeutics that allow an extended 
serum half-life and thereby limit the frequency of administration, particularly important in 
chronic diseases. PEGylation is the attachment of PEG to lysine residues on the protein 
surface. More than 10 PEGylated therapeutics are currently used in the clinic, of which one is 
used for the treatment of MS (PEG-IFN). Interestingly, a study by the ADVANCE trial showed 
a frequency of NAb to PEG-IFN in less than 1% of the treated MS patients that were followed 
for two years (240). However, there are some difficulties using the PEGylation technology to 
improve protein therapeutics. For example, the attachment of PEG to the drug molecule 
allows binding around the active sites of the molecule and could reduce the drugs activity and 
hence efficacy. However, anti-PEG antibodies can also form and we do not yet know what 
impact they will have on treatment and patients. 
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5.1.3.3 Affibody molecules 
Lastly, an interesting candidate for the treatment of chronic inflammatory diseases is Affibody 
molecules (316). Due to its small size (around 6 kDa) the molecules can easily penetrate the 
tissue and compared to larger proteins the same volume would allow a higher molar dose. 
Comparatively, IgG antibodies have a size of 150 kDa. Affibody molecules could also, 
potentially, be administrated via alternative routes to the skin site. Since the skin is a major 
immunological barrier and, potentially, a sub-optimal administration route with regards to 
ADA development (as addressed in study V), the next generation of biopharmaceuticals might 
have to be designed in a way to overcome such problems. These include, for example, finding 
ways to survive an acidic environment when drug administration is via the oral route. 
5.1.3.4 Conclusions 
ADA need not to be a limitation of biological treatments if they are taken into account during 
drug development, managed well in the clinics, and recorded in patient registries for 
monitoring of future issues, should they manifest.   
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